Tracking and delivery confirmation of pharmaceutical products

Information

  • Patent Grant
  • 10529044
  • Patent Number
    10,529,044
  • Date Filed
    Thursday, May 19, 2011
    13 years ago
  • Date Issued
    Tuesday, January 7, 2020
    4 years ago
Abstract
A system and method are disclosed that track a deliverable to a user. The system includes an identifier or tag secured to the deliverable, a computer system for interrogating the identifier, and a personal device in communication with the computer system, wherein the personal device is held by the user at the time the user is administered the deliverable to detect the unique identity associated with the identifier device and confirms delivery of the deliverable to the user. The method includes attaching an identifiable tag that produces a unique signature to the deliverable, interrogating the tag at about the time of delivery to the user, and confirming that the user has been administered the deliverable through detecting the identifiable tag.
Description
FIELD OF THE INVENTION

The present invention is related to electronic systems for tracking products from manufacturer to consumer and, more specifically, to multiple devices including a mobile communication unit and an identifiable tag that is associated with a pharmaceutical product to confirm source of the dosage, the proper type and amount of dose, and delivery to the patient.


INTRODUCTION

In many instances there is a need for tracking pharmaceutical products from the manufacturer to the patient. In so doing, the provider or dispenser of the pharmaceutical products is able to confirm that the pharmaceutical products come from a reliable source and that the pharmaceutical products are not counterfeit. Additionally, in many remote areas, where access to medical facilities is limited, it is often the case wherein the provider is not able to read or understand information provided on the label. In such situations, the provider needs a simple and effective way to identify the patient and determine what medication should be delivered, especially when there are various medications from which to choose.


Thus, what is needed is a system and method that can track pharmaceutical products from the manufacturer along the supply chain to the patient as well as confirm actual delivery of the pharmaceutical products to the patient.


SUMMARY

The present disclosure includes a system for tracking pharmaceutical products from manufacturer to the patient. The present invention also includes systems for confirming delivery of the pharmaceutical products to the patient; the delivery confirmation includes systems and methods for confirming delivery of the right dose and the correct quantity. The present invention includes systems that include circuitry and components that can function within certain environments that include a conducting fluid. One example of such an environment is outside or inside a container that houses the conducting fluid, such as a sealed bag with a solution, which includes an IV bag. Another example is within the body of a living organism, such as an animal or a human. According to various aspects of the present invention, part of the system is ingestible or injectible and, hence, can be taken by or injected to or inhaled by the patient.


In one aspect, a computer system is provided to track a medication from manufacturer to a patient, to enable a care provider to determine the origin of the medication and to confirm that at least one of the right type and the right dosage of the medication was delivered to the patient. The computer system comprising: a processor operative to: receive a unique identity of an identifier device secured to a dosage of medication, wherein the identifier device comprises the unique identity that is associated with at least one of the manufacturer and the medication; receive information from a patient interface device in communication with the computer and the patient, wherein at the time the patient takes the medication, the patient interface device is operative to detect the unique identity associated with the identifier device and confirm delivery of the medication to the patient; and receive the detected unique identity associated with the identifier device detected via the patient interface device and the confirmation of delivery of the medication to the patient via the patient interface device; wherein the processor is operative to confirm the origin of the medication and the type of the medication based at least on the unique identity of the identifier device.


In another aspect of the computer system, the processor is operative to interrogate the identifier device.


In another aspect of the computer system, the identifier device comprises a tag provided with circuitry, wherein the tag is secured to the dosage of the medication, and wherein the processor is operative to read the unique identity from the tag.


In another aspect of the computer system, the tag is secured to a dosage of medication in the form of a pill.


In another aspect of the computer system, the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air.


In another aspect of the computer system, the syringe comprises a needle and wherein the needle comprises at least one contact point coupled to the tag.


In another aspect of the computer system, the processor is operative to communicate with a datacenter database to at least one of retrieve medical information about the patient and provide information related to the medication to be administered to the patient.


In another aspect of the computer system, the processor is operative to: communicate with at least one of a database or a processing system at the datacenter; transmit information to the processing system; receive information from the processing system, wherein the processing system is operative to access the information in the database of the data center and provide the information to the patient through the computer.


In another aspect of the computer system, the processor is operative to validate at least one of the type and dosage selected by the care provider prior to dispensing the medication to the patient.


In another aspect of the computer system, the processor is operative to communicate with an interrogation unit coupled to the identifier device, wherein the interrogation unit is operative to interrogate the identifier device secured to the medication and receive the unique identity of the identifier device to confirm the origin of the medication and the type of the medication, wherein the computer is operative to interrogate the interrogation unit and receive the unique identity of the identifier from the interrogation unit.


In another aspect of the computer system, the processor is operative to: communicate with a memory of the interrogation unit; and receive the unique identity of the identifier stored in the memory of the interrogation unit.


In another aspect of the computer system, the processor is operative to receive biometric parameters from the patient interface device, wherein the biometric parameters can identify the patient.


In another aspect of the computer system, the processor is operative to receive an image of the patient captured by a camera on the patient interface device.


In another aspect of the computer system, a display provides information associated with the patient, wherein the information comprises any of an image of the patient, medical history of the patient, and a next type and dose of medication to deliver to the patient.


In one aspect, a computer-implemented method is provided to track a medication from manufacturer to a patient, to enable a care provider to determine the origin of the medication and to confirm that at least one of the right type and the right dosage of medication was delivered to the patient, the computer comprising a processor. The method comprising: receiving by the processor a unique identity of the identifier device secured to a dosage of medication, wherein the identifier device comprises the unique identity that is associated with at least one of the manufacturer and the medication; receiving by the processor information from a patient interface device in communication with the computer and the patient, wherein at the time the patient takes the medication, the patient interface device is operative to detect the unique identity associated with the identifier device and confirm delivery of the medication to the patient; receiving by the processor the detected unique identity associated with the identifier device detected from the patient interface device and the confirmation of delivery of the medication to the patient from the patient interface device; and confirming the origin of the medication and the type of the medication based at least on the unique identity of the identifier device.


In another aspect, the computer-implemented method comprises interrogating by the processor the identifier device.


In another, the computer-implemented method comprises receiving by the processor the unique identity from a tag, wherein the identifier device comprises the tag provided with circuitry, wherein the tag is secured to the dosage of the medication, the method.


In another aspect, the computer-implemented method comprises receiving by the processor the unique identity from the tag, wherein the tag is secured to a dosage of medication in the form of a pill.


In another aspect, the computer-implemented method comprises receiving by the processor the unique identity from the tag, wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air.


In another aspect, the computer-implemented method comprises receiving by the processor the unique identity from the tag, wherein the syringe comprises a needle, and wherein the needle comprises at least one contact point coupled to the tag.


In another aspect, the computer-implemented method comprises at least one of: retrieving by the processor medical information about the patient from a datacenter database; and providing by the processor information related to the medication to be administered to the patient.


In another aspect, the computer-implemented method comprises transmitting by the processor information to the processing system; receiving by the processor information from the processing system, wherein the processing system is operative to access the information in the database of the data center and provide the information to the patient through the computer.


In another aspect, the computer-implemented method comprises validating by the processor at least one of the type and dosage selected by the care provider prior to dispensing the medication to the patient.


In another aspect, the computer-implemented method comprises interrogating by the processor operative an interrogation unit coupled to the identifier device, wherein the interrogation unit is operative to interrogate the identifier device secured to a medication and receive the unique identity of the identifier device to confirm the origin of the medication and the type of the medication; and receiving by the computer the unique identity of the identifier from the interrogation unit.


In another aspect, the computer-implemented method comprises communicating by the processor with a memory of the interrogation unit; and receiving by the processor the unique identity of the identifier stored in the memory of the interrogation unit.


In another aspect, the computer-implemented method comprises receiving by the processor biometric parameters from the patient interface device, wherein the biometric parameters can identify the patient.


In another aspect, the computer-implemented method comprises receiving by the processor an image of the patient captured by a camera on the patient interface device. In another aspect, the computer-implemented method comprises displaying on a display coupled to the processor information associated with the patient, wherein the information comprises any of an image of the patient, medical history of the patient, and a next type and dose of medication to deliver to the patient.


In one aspect, an apparatus is provided. The apparatus comprising: at least one contact point configured to electrically engage an identifier device secured to a medication, wherein the identifier device comprises a unique identity that is associated with at least one of the manufacturer and the medication; an interrogation unit coupled to the at least one contact point, wherein the interrogation unit is operative to interrogate the identifier device to obtain the unique identity; and a communication module coupled to the interrogation unit, wherein the communication module is operative to transmit the unique identification.


In another aspect of the apparatus, the interrogation unit is operative to read the unique identity associated with the identifier device.


In another aspect, the communication module is operative to transmit the unique identity associated with the identifier device to a computer in communication with the communication module.


In another aspect of the apparatus, the apparatus comprises a memory coupled to the interrogation unit to store the unique identity associated with the identifier device.


In another aspect, the interrogation unit is operative to read the unique identity from a tag provided with circuitry, wherein the tag is secured to the dosage of the medication.


In another aspect of the apparatus, the interrogation unit is operative to read the unique identity from the tag, wherein the tag is secured to a dosage of medication in the form of a pill.


In another aspect of the apparatus, the interrogation unit is operative to read the unique identity from the tag, wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air.


In another aspect of the apparatus, the interrogation unit is operative to read the unique identity from the tag, wherein the syringe comprises a needle and wherein the needle comprises at least one contact point coupled to the tag.


In one aspect, a method is provided. The method comprising: electrically engaging by an interrogation unit an identifier device secured to a medication with at least one contact point coupled to the interrogation unit, wherein the identifier device comprises a unique identity that is associated with at least one of the manufacturer and the medication; interrogating the identifier device for the unique identity; and transmitting the unique identification by a communication module coupled to the interrogation unit.


In another aspect, the method comprises reading by the interrogation unit the unique identity associated with the identifier device.


In another aspect, the method comprises transmitting by the communication module the unique identity associated with the identifier device to a computer in communication with the communication module.


In another aspect, the method comprises storing by the interrogation unit the unique identity associated with the identifier device in a memory, wherein the memory is coupled to the interrogation unit.


In another aspect, the method comprises receiving by the interrogation unit the unique identity from a tag, wherein the identifier device comprises the tag provided with circuitry, wherein the tag is secured to the dosage of the medication.


In another aspect, the method comprises receiving by the interrogation unit the unique identity from the tag, wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air.


In another aspect, the method comprises receiving by the interrogation unit the unique identity from the tag, wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air.


In another aspect, the method comprises receiving by the interrogation unit the unique identity from the tag, wherein the syringe comprises a needle, and wherein the needle comprises at least one contact point coupled to the tag.


In one aspect, a patient interface device is provided. The patient interface comprising: a housing defining an outer surface, wherein the housing is configured to held by a patient; at least one contact point exposed on the outer surface portion of the housing, wherein the at least one contact point is positioned to be physically contacted by the patient to detect biometric information associated with the patient, wherein the at least one contact point is configured to detect at least one physiological parameter associated with the patient; a control module coupled to the at least one contact point, wherein the at least one contact point is coupled to the control module to capture the at least one physiological parameter associated with the patient; and a communication module coupled to the control unit to transmit the at least one physiological parameter to a computer in communication with the communication module.


In another aspect of the patient interface device, the patient interface device comprises a power source coupled to the control module.


In another aspect of the patient interface device, the patient interface device comprises an image generation unit to capture an image of the patient, wherein the image generation unit is coupled to the control module and is configured to capture the image of the patient and to transmit the captured image to the control module.


In another aspect of the patient interface device, the control module is operative to activate the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.


In one aspect, a method is provided. The method comprising: contacting by a patient at least one contact point exposed on an outer surface portion of a housing, wherein the at least one contact point is positioned to be physically contacted by the patient to detect biometric information associated with the patient, wherein the at least one contact point is configured to detect at least one physiological parameter associated with the patient; capturing by a control module coupled to the at least one contact point at least one physiological parameter associated with the patient; and transmitting by a communication module coupled to the control unit the at least one physiological parameter to a computer in communication with the communication module.


In another aspect, the method comprises scanning by the at least contact point a fingerprint associated with the patient; confirming by the control module fingerprint information.


In another aspect, the method comprises capturing an image of the patient by an image generation unit, wherein the image generation unit is coupled to the control module;


and transmitting by the image generation unit the captured image of the patient to the control module.


In another aspect, the method comprises activating by the control module the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.


In one aspect, a patient interface device is provided. The patient interface device comprising: a housing defining an outer surface, wherein the housing is configured to held by a patient; at least one contact point exposed on the outer surface portion of the housing, wherein the at least one contact point is positioned to be physically contacted by the patient to detect biometric information associated with the patient, wherein the at least one contact point is configured to detect at least one physiological parameter associated with the patient; a control module coupled to the at least one contact point, wherein the at least one contact point is coupled to the control module to capture the at least one physiological parameter associated with the patient; and a communication module coupled to the control unit to transmit the at least one physiological parameter to a computer in communication with the communication module.


In another aspect, the patient interface device comprises a power source coupled to the control module.


In another aspect, the patient interface device comprises an image generation unit to capture an image of the patient, wherein the image generation unit is coupled to the control module and is configured to capture the image of the patient and to transmit the captured image to the control module.


In another aspect of the patient interface device, the control module is operative to activate the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.


In one aspect, a method is provided. The method comprising: contacting by a patient at least one contact point exposed on an outer surface portion of a housing, wherein the at least one contact point is positioned to be physically contacted by the patient to detect biometric information associated with the patient, wherein the at least one contact point is configured to detect at least one physiological parameter associated with the patient; capturing by a control module coupled to the at least one contact point at least one physiological parameter associated with the patient; and transmitting by a communication module coupled to the control unit the at least one physiological parameter to a computer in communication with the communication module.


In another aspect, the method comprises scanning by the at least contact point a fingerprint associated with the patient; confirming by the control module fingerprint information.


In another aspect, the method comprises capturing an image of the patient by an image generation unit, wherein the image generation unit is coupled to the control module; and transmitting by the image generation unit the captured image of the patient to the control module.


In another aspect, the method comprises activating by the control module the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.


Notwithstanding the claims and the above aspects of the present invention, in various other aspects, the present invention also may be defined by the following clauses:


1. A computer system to track medication from manufacturer to a patient, to enable a care provider to determine the origin of the medication and to confirm that at least one of the right type and the right dosage of medication was delivered to the patient, the computer system comprising:


a processor operative to:

    • receive a unique identity of an identifier device secured to a dosage of medication to confirm the origin of the medication and the type of the medication, wherein the identifier device comprises the unique identity that is associated with at least one of the manufacturer and the medication;
    • receive information from a patient interface device in communication with the computer and the patient, wherein at the time the patient takes the medication, the patient interface device is operative to detect the unique identity associated with the identifier device and confirm delivery of the medication to the patient; and
    • receive the detected unique identity associated with the identifier device detected from the patient interface device and the confirmation of delivery of the medication to the patient from the patient interface device.


      2. The computer system of clause 1, wherein the processor is operative to interrogate the identifier device.


      3. The computer system of clause 1 or 2, wherein the identifier device comprises a tag provided with circuitry, wherein the tag is secured to the dosage of the medication, and wherein the processor is operative to read the unique identity from the tag.


      4. The computer system of any of the preceding clauses, wherein the tag is secured to a dosage of medication in the form of a pill.


      5. The computer system of any of the preceding clauses 1-3, wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air.


      6. The computer system of clause 5, wherein the syringe comprises a needle and wherein the needle comprises at least one contact point coupled to the tag.


      7. The computer system according to any of the preceding clauses wherein the processor is operative to communicate with a datacenter database to at least one of retrieve medical information about the patient and provide information related to the medication to be administered to the patient.


      8. The computer system of clause 7, wherein the processor is operative to:


communicate with at least one of a database or a processing system at the datacenter;


transmit information to the processing system;


receive information from the processing system, wherein the processing system is operative to access the information in the database of the data center and provide the information to the patient through the computer.


9. The computer system according to any of the preceding clauses wherein the processor is operative to validate at least one of the type and dosage selected by the care provider prior to dispensing the medication to the patient.


10. The computer system according to any of the preceding clauses wherein the processor is operative to communicate with an interrogation unit coupled to the identifier device, wherein the interrogation unit is operative to interrogate the identifier device secured to the medication and receive the unique identity of the identifier device to confirm the origin of the medication and the type of the medication, wherein the computer is operative to interrogate the interrogation unit and receive the unique identity of the identifier from the interrogation unit.


11. The computer system of clause 10, wherein the processor is operative to:


communicate with a memory of the interrogation unit; and


receive the unique identity of the identifier stored in the memory of the interrogation unit.


12. The computer system according to any of the preceding clauses wherein the processor is operative to receive biometric parameters from the patient interface device, wherein the biometric parameters can identify the patient, or wherein the processor is operative to receive an image of the patient captured by a camera on the patient interface device.


13. The computer system according to any of the preceding clauses comprising a display to provide information associated with the patient, wherein the information comprises any of an image of the patient, medical history of the patient, and a next type and dose of medication to deliver to the patient.


14. A computer-implemented method to track medication from manufacturer to a patient, which preferably uses a computer system according to any of the preceding clauses, to enable a care provider to determine the origin of the medication and to confirm that at least one of the right type and the right dosage of medication was delivered to the patient, the computer comprising a processor, the method comprising:


receiving by the processor a unique identity of the identifier device secured to a dosage of medication to confirm the origin of the medication and the type of the medication, wherein the identifier device comprises the unique identity that is associated with at least one of the manufacturer and the medication;


receiving by the processor information from a patient interface device in communication with the computer and the patient, wherein at the time the patient takes the medication, the patient interface device is operative to detect the unique identity associated with the identifier device and confirm delivery of the medication to the patient; and


receiving by the processor the detected unique identity associated with the identifier device detected from the patient interface device and the confirmation of delivery of the medication to the patient from the patient interface device.


15. The computer-implemented method of clause 15, comprising interrogating by the processor the identifier device.


16. The computer-implemented method of clause 14 or 15, comprising receiving by the processor the unique identity from a tag, wherein the identifier device comprises the tag provided with circuitry, wherein the tag is secured to the dosage of the medication, the method.


17. The computer-implemented method of clause 16, comprising receiving by the processor the unique identity from the tag, wherein the tag is secured to a dosage of medication in the form of a pill or wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air, preferably comprising receiving by the processor the unique identity from the tag, wherein the syringe comprises a needle, and wherein the needle comprises at least one contact point coupled to the tag.


18. The computer-implemented according to any of the clauses 14-17 comprising at least one of:


retrieving by the processor medical information about the patient from a datacenter database; and


providing by the processor information related to the medication to be administered to the patient.


19. The computer-implemented method of clause 18, comprising:


transmitting by the processor information to the processing system; receiving by the processor information from the processing system, wherein the processing system is operative to access the information in the database of the data center and provide the information to the patient through the computer.


20. The computer-implemented method according to any of the clauses 14-19, comprising:


validating by the processor at least one of the type and dosage selected by the care provider prior to dispensing the medication to the patient.


21. The computer-implemented method according to any of the clauses 14-20 comprising:


interrogating by the processor operative an interrogation unit coupled to the identifier device, wherein the interrogation unit is operative to interrogate the identifier device secured to the medication and receive the unique identity of the identifier device to confirm the origin of the medication and the type of the medication; and


receiving by the computer the unique identity of the identifier from the interrogation unit.


22. The computer-implemented method of clause 21, comprising:


communicating by the processor with a memory of the interrogation unit; and


receiving by the processor the unique identity of the identifier stored in the memory of the interrogation unit.


23. The computer-implemented method according to any of the clauses 14-22 comprising:


receiving by the processor biometric parameters from the patient interface device, wherein the biometric parameters can identify the patient.


24. The computer-implemented method according to any of the clauses 14-23 comprising:


receiving by the processor an image of the patient captured by a camera on the patient interface device.


25. The computer-implemented method according to any of the clauses 14-24 comprising:


displaying on a display coupled to the processor information associated with the patient, wherein the information comprises any of an image of the patient, medical history of the patient, and a next type and dose of medication to deliver to the patient.


26. An apparatus, comprising:


at least one contact point configured to electrically engage an identifier device secured to a medication, wherein the identifier device comprises a unique identity that is associated with at least one of the manufacturer and the medication;


an interrogation unit coupled to the at least one contact point, wherein the interrogation unit is operative to interrogate the identifier device to obtain the unique identity; and


a communication module coupled to the interrogation unit, wherein the communication module is operative to transmit the unique identification.


27. The apparatus of clause 26, wherein the interrogation unit is operative to read the unique identity associated with the identifier device.


28. The apparatus of clause 26 or 27 wherein the communication module is operative to transmit the unique identity associated with the identifier device to a computer in communication with the communication module.


29. The apparatus according to any of the clauses 26-28 comprising a memory coupled to the interrogation unit to store the unique identity associated with the identifier device.


30. The apparatus according to any of the clauses 26-29 wherein the interrogation unit is operative to read the unique identity from a tag provided with circuitry, wherein the tag is secured to the dosage of the medication, preferably wherein the interrogation unit is operative to read the unique identity from the tag, wherein the tag is secured to a dosage of medication in the form of a pill, or wherein the interrogation unit is operative to read the unique identity from the tag, wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air, preferably wherein the syringe comprises a needle and wherein the needle comprises at least one contact point coupled to the tag.


31. A method, comprising:


electrically engaging by an interrogation unit an identifier device secured to a medication with at least one contact point coupled to the interrogation unit, wherein the identifier device comprises a unique identity that is associated with at least one of the manufacturer and the medication;


interrogating the identifier device for the unique identity; and


transmitting the unique identification by a communication module coupled to the interrogation unit.


32. The method of clause 31, comprising reading by the interrogation unit the unique identity associated with the identifier device.


33. The method of clause 31 or 32 comprising transmitting by the communication module the unique identity associated with the identifier device to a computer in communication with the communication module.


34. The method according to any of the clauses 31-33 comprising storing by the interrogation unit the unique identity associated with the identifier device in a memory, wherein the memory is coupled to the interrogation unit.


35. The method according to any of the clauses 31-34 comprising receiving by the interrogation unit the unique identity from a tag, wherein the identifier device comprises the tag provided with circuitry, wherein the tag is secured to the dosage of the medication.


36. The method of clause 35, comprising receiving by the interrogation unit the unique identity from the tag, wherein the tag is secured to a syringe configured for delivery of the dosage of medication, wherein the syringe comprises a safety component which is activated upon exposure to air, preferably wherein the syringe comprises a needle, and wherein the needle comprises at least one contact point coupled to the tag.


37. A patient interface device, comprising:


a housing defining an outer surface, wherein the housing is configured to held by a patient;


at least one contact point exposed on the outer surface portion of the housing, wherein the at least one contact point is positioned to be physically contacted by the patient to detect biometric information associated with the patient, wherein the at least one contact point is configured to detect at least one physiological parameter associated with the patient;


a control module coupled to the at least one contact point, wherein the at least one contact point is coupled to the control module to capture the at least one physiological parameter associated with the patient; and


a communication module coupled to the control unit to transmit the at least one physiological parameter to a computer in communication with the communication module.


38. The patient interface device of clause 37, comprising a power source coupled to the control module.


39. The patient interface device of clause 37 or 38 comprising an image generation unit to capture an image of the patient, wherein the image generation unit is coupled to the control module and is configured to capture the image of the patient and to transmit the captured image to the control module.


40. The patient interface device according to any of the clauses 37-39 wherein the control module is operative to activate the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.


41. A method, comprising:


contacting by a patient at least one contact point exposed on an outer surface portion of a housing, wherein the at least one contact point is positioned to be physically contacted by the patient to detect biometric information associated with the patient, wherein the at least one contact point is configured to detect at least one physiological parameter associated with the patient;


capturing by a control module coupled to the at least one contact point at least one physiological parameter associated with the patient; and


transmitting by a communication module coupled to the control unit the at least one physiological parameter to a computer in communication with the communication module.


42. The method of clause 41, comprising:


scanning by the at least contact point a fingerprint associated with the patient;


confirming by the control module fingerprint information.


43. The method of clause 41 or 42, comprising:


capturing an image of the patient by an image generation unit, wherein the image generation unit is coupled to the control module; and


transmitting by the image generation unit the captured image of the patient to the control module.


44. The method according to any of the clauses 41-43 comprising activating by the control module the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.


45. System for tracking a product from a manufacturer along a supply chain to a user, the system comprising:

    • Identifying means associated with the product for identifying the product,
    • Interrogating means for interrogating the identifying means.


      46. System according to clause 45 wherein the product is a medicine and the user is a patient, wherein the system enables a care provider to determine the origin of the medicine.


      47. System according to clause 45 or 46, further comprising patient communication means for communicating identity of the medicine to the patient.


      48. System according to any of the preceding clauses 45-47 wherein the identifying means comprises a device secured to the product.


      49. System according to clause 48, wherein the identifying means has a unique identity associated with the manufacturer and/or the product.


      50. System according to any of the preceding clauses 46-49 wherein the system confirms that a correct dosage and/or correct type of medication was delivered to the patient.


      51. System according to any of the preceding clauses 45-50 wherein the interrogating means comprises a computer system which reads the unique identity of the identifying means.


      52. System according to clause 51 wherein the computer system communicates with a database to retrieve user information and/or product information.


      53. System according to clauses 52 wherein the user information is patient information, and wherein the product information is information related to the medicament to be administered to the patient.


      54. System according to any of the clauses 51-53 wherein the computer system validates at least one of the type and dosage prior to dispensing.


      55. System according to any of the preceding clauses 47-54, wherein the patient communication means is configured to be in physical communication with the patient at the time the patient takes the medication, and is in communication with the computer system, the patient communication means being a personal device which detects the unique identity of the identifying means and confirms delivery of the product.


      56. System according to any of the preceding clauses 45-55 wherein the identifying means is a tag provided with circuitry, which tag is secured to a pill, and which circuitry is broken if the tag is removed from the pill.


      57. System according to any of the preceding clauses 45-55 wherein the identifying means is a tag, which tag is secured to a syringe, wherein the tag and/or syringe comprises a safety component which is activated on exposure to air.


      58. System according to clauses 56 or 57 wherein the tag cannot be interrogated if the medicament is not delivered within a pre-determined time period.


      59. System according to clauses 57 or 58 wherein a needle of the syringe includes a contact point connected to the tag.


      60. An interface device for confirming delivery of medication to a patient, preferably for use in a system according to any of the preceding clauses 45-59, the device comprising: a control module, wherein the control modules includes a communication module and a memory unit;


a contact point to detect at least one physiological parameter associated with the patient, wherein the contact point is connected to the control module and captures at least one physiological parameter associated with the patient and transmits that information to the patient; and


an image generation unit to capture the patient's image, wherein the image generation unit is connected to the control module and captures the image of the patient and transmits the image to the control module,


wherein the control module activates the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.


61. System according to any of the preceding clauses 45-59, further comprising a device according to clause 60.


62. Method for tracking a product from a manufacturer along a supply chain to a user comprising the steps of attaching identifying means to a product, and interrogating the identifying means.


63. Method according to clause 62 further comprising the step of confirming receipt of the product to the user.


64. Method according to clause 62 or 63 using a system, device or apparatus according to any of the preceding.


65. A pill comprising a tag, which tag is provided with circuitry.


66. A syringe comprising a tag, wherein the tag and/or syringe comprises a safety component which is activated on exposure to air.


67. System to track medication from manufacturer to a patient, to enable a care provider to determine the origin of the medication and to confirm that at least one of the right type and the right dosage of medication was delivered to the patient, the system comprising:


an identifier device secured to the medication, wherein the identifier device has a unique identity that is associated with at least one of the manufacturer and the medication;


a computer system for interrogating the identifier device,


wherein the computer system reads the unique identity of the identifier device to confirm the origin of the medication and the type of the medication and


wherein the computer system communicates with a database to at least one of retrieve medical information about the patient and provide information related to the medication to be administered to the patient and


wherein the computer system validates at least one of the type and dosage selected by the care provider prior to dispensing to the patient; and


a personal device in communication with the computer system, wherein the personal device is configured to be in physical communication with the patient at the time the patient takes the medication to detect the unique identity associated with the identifier device and confirm delivery of the medication to the patient.


68. Method to track and guide a care provider to deliver a proper type and dose of medication to a patient such that a care provider confirms that the medication is traceable to a known origin, the method comprising the steps of:


attaching an identifiable tag that produces a unique signature to the medication at the origin when the medication is created;


interrogating the tag at about the time of delivery to the patient to determine if the medication is the original medication and to confirm that that the correct medication has been selected for the patient; and


confirming that the patient has taken or received the medication through detecting the identifiable tag's unique signature through the patient's body based on communication of the identifiable tag with the patient.


69. System to track a deliverable to a user, the system comprising:


an identifier device secured to the deliverable, wherein the identifier device has a unique identity that is associated with the deliverable;


a computer system for interrogating the identifier device,


wherein the computer system identifies the identifier device to confirm information associated with the deliverable and


wherein the computer system communicates with a database to at least one of retrieve information associated with the user and provide a care provider with the information associated with the deliverable to be administered to the user and


wherein the computer system validates the information associated with the deliverable provided by the care provider prior to administration to the user; and


a personal device in communication with the computer system, wherein the personal device is configured to be held by the user at the time the user is administered the deliverable to detect the unique identity associated with the identifier device and to confirm delivery of the deliverable to the user.


70. Method to track and guide a care provider to deliver a deliverable to a user such that the care provider can confirm that the deliverable is traceable to a known origin, the method comprising the steps of:


providing an identifiable tag that produces a unique signature, the identifiable tag physically associated with the deliverable;


interrogating an identifiable tag associated with the deliverable at about the time of delivery to the user to determine if the deliverable is the intended deliverable and confirm that the care provider has selected the correct deliverable; and


confirming that the user has been administered the deliverable through detecting the identifiable tag's unique signature based on contact of the identifiable tag with the user.


71. Interface device for confirming delivery of medication to a patient, the device comprising:


a control module, wherein the control modules includes a communication module and a memory unit;


a contact point to detect at least one physiological parameter associated with the patient, wherein the contact point is connected to the control module and captures at least one physiological parameter associated with the patient and transmits that information to the patient; and


an image generation unit to capture the patient's image, wherein the image generation unit is connected to the control module and captures the image of the patient and transmits the image to the control module,


wherein the control module activates the image generation unit to capture the image of the patient when the contact point detects there is a change in the physiological parameter of the patient during the time the patient is in contact with the contact point and when the control module detects a current flow through the patient.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows a system for tracking medication from origin to patient as well as confirmation of delivery of the correct type and dose of medication.



FIG. 2A shows a needle of a syringe used for delivery of medication in accordance with one aspect of the present invention.



FIG. 2B shows a needle of a syringe used for delivery of medication in accordance with another aspect of the present invention.



FIG. 2C shows a cut-away section of a sleeve for holding the syringe of FIG. 2A and FIG. 2B in accordance with an aspect of the present invention.



FIG. 3 shows a functional block diagram representation of an identity confirmation device as used in FIG. 1 in accordance with one aspect of the present invention.



FIG. 4 shows one aspect of a tag.





DETAILED DESCRIPTION

Referring now to FIG. 1, a system 10 includes a device 40, a mobile computer 50, and a patient identity confirmation device 70. The system 10 communicates with a central data center 80. In accordance with various aspects of the present invention, there are at least two methods disclosed for delivery of medication: a pill 20 and a syringe 30.


However, the scope of the present invention is not limited by delivery methods used. For example, the medication may be delivered by a patch, an inhaler, or an ointment. Further, the term “pill” includes various form factors of ingestible medicaments and carriers, e.g., capsules, gel caps, placebos, over capsulation carriers or vehicles, etc. In the event a patch is used, then the tag can be secured to the patch. If an ointment is used, then the tag may be included with ointment and delivery and tracking can be confirmed once the ointment is applied. At the origin or location of manufacturing of the medication, an identifiable tag is associated with the medication regardless of the type of medication or method of delivery/dispensing of the medication to the patient. The identifiable tag is similar to an ingestible event marker or an ionic emission module (IEM). The IEM can be ingested and is capable of providing an identifiable signature and is unique. The IEM is disclosed in greater detail in U.S. patent application Ser. No. 12/564,017 entitled COMMUNICATION SYSTEM WITH PARTIAL POWER SOURCE filed on Sep. 21, 2009, and published as 2010-0081894 A1 dated Apr. 1, 2010, which is incorporated herein by reference in its entirety.


In accordance with other aspects of the present invention, the identifiable tags may include bar codes on packaging that uniquely identify the medication in the package, which package includes tamper proof seals. Thus the care provider would use the mobile computer 50 to scan the bar code or capture an image of the bar code that is transmitted to the data center 80 for confirmation.


With respect to the pill 20, an identifiable tag 22 is shown secured to one side of the pill 20. Surrounding the tag 22 is a conducting surface 24. One surface of the tag 22 is exposed and the other surface of the tag 22 is electrically coupled to the surface 24 via a conduction path 26. The conducting surface 24 can be created using a variety of techniques, e.g., any ingestible conducting ink technology. To prevent removal of the tag 22 from the pill 20, the tag 22 is secured in such a way to cause destruction of the circuitry of the tag 22 if attempts are made to separate it from the medication. Additionally, including the conducting surface 24 around the tag 22 further prevents tampering with and removal of the tag 22. Specifically, if the tag 22 is removed from the pill 20, then the conducting surface 24 and the path 26 will be separated from the tag 22 thereby preventing interrogation of the tag 22 by a device 40.


The device 40 includes contact points 42 and 44, each of which is connected to an interrogation unit 46. The device 40 also includes a power source, which is not shown. The interrogation unit 46 is connected to a communication module 48. To confirm the origin of the pill 20 as well the type and dose, the pill 20 is placed in the opening 40a and comes into contact with contact points 42 and 44. The interrogation unit 46 can then read the identity of the tag 22. The identity of the tag 22 is then communicated to a mobile computer 50. The communication link 52 between the device 40 and the mobile computer 50 is any wireless communication link, such as Bluetooth™ technology or similar wireless technology. In another aspect, the device 40 may be part of the computer 50 as well.


According to another aspect of the present invention, the device 40 may include a memory for storing the information for later transmission or communication as well as confirmation in the event the communication link between the device 40 and the mobile computer 50 is interrupted or lost.


Additionally, in accordance with another aspect of the present invention, the device 40 may be directly connected to the mobile computer 50 with a physical link (not shown), such as a wired connection, such as a Universal Serial Bus (USB). The mobile computer 50 is then able to confirm the origin of the medication and other information associated with correct delivery of the type and dose of medication to a patient 60. The computer 50 is shown with a display 58. The display 58 can provide information such as an image of the patient, patient's medical history, the next type and dose of medication to deliver to the patient. In accordance with various aspects of the present invention, the mobile computer 50 may be any device that includes a display and wireless communication capabilities, such as a mobile communication device, a mobile phone, or a laptop computer with wireless communication unit. Furthermore, the mobile computer 50 includes audio output 50a and an audio input 50b, which can be used together to simulate a modem and create a data channel for communication. Also, the mobile computer 50 is capable of communication using various communications protocol(s), e.g., Short Message Service (SMS) such that information is transmitted to a destination through mobile phone communication channels.


With respect to the syringe 30, an identifiable tag 32 is secured to the syringe 30. To ensure that the tag 32 cannot be removed from the syringe 30 and reattached to a different syringe, the syringe and/or tag include(s) a safety component, e.g., the tag 32 includes a layer that is activated once exposed to air, such as a zinc battery. Thus, upon manufacture, each syringe 30 is secured within a hermetically sealed package to preserve the tag 32. Once the package is opened, the tag 32 is exposed to the air and, hence, activated. Thus, if the package is opened and the medication is not delivered within a short period of time, such a few minutes, then the tag 32 is deactivated and cannot be interrogated later. In accordance with one aspect of the present invention, the layer of the tag 32 is a zinc-based battery that is activated upon contact with the surrounding air and, hence, powers up the tag 32.


Once the syringe 30 is removed from the package and the care provider is ready to deliver the medication to the patient, the syringe 30 is placed inside the sleeve 34. The sleeve 34 can detect and capture the identity of the tag 32. The sleeve 34 transmits the information associated with the tag 32 secured to the syringe 30 via a physical connection 54 between the mobile computer 50 and the sleeve 34. In accordance with another aspect of the present invention, the sleeve 34 may be in communication with the mobile computer 50 via a wireless connection, not shown. As the needle of the syringe 30 comes into contact with the patient 60, then the circuit is completed as shown through the patient identity confirmation device 70.


Referring now to FIG. 2A and FIG. 2B, in accordance with another aspect of the present invention, the needle of the syringe 30 may include specific contact points 36 that are connected to the tag 32 via connection 38. The contact points 36 are positioned along at the end of the syringe 30 or on the needle such that contact with the skin of the patient completes a circuit that is then used to activate the tag 32 to transmit a unique signature or identity that represents delivery of the medication to the patient 60.


Referring now to FIG. 2C, the contact points 36 are electrically coupled to the tag 32. The tag 32 is electrically coupled to the sleeve 34 as the syringe 30 is placed inside the sleeve 34 through a contact point 34a. The contact point 34a makes contact with the tag 32 to allow electrical signals to pass between the tag 32, through the connection 54, and the mobile computer 50. A stop tab 34b is positioned within the sleeve 34 to ensure proper alignment of the contact point 34a with the tag 32.


Referring now to FIG. 1 and FIG. 3, the patient identity confirmation device 70 is shown connected to the mobile computer 50 via a connection or link 56. The patient identity confirmation device 70 includes thumb pads or contact points 72 and 74 exposed on the surface of the patient identity confirmation device 70. The contact points 72 and 74 may be any form of biometric detection contacts in accordance with various aspects of the present invention. For example, the contact point may scan and confirm fingerprint information. In accordance with another aspect of the present invention, the contact points may detect the physiological parameters of the patient, such as temperature, or other biometric parameters that can identify the patient, including DNA. The contact points 72 and 74 are electrically coupled to a control unit 70a within the patient identity confirmation device 70. In accordance with one aspect of the present invention, a power source 70b is electrically coupled to the control unit 70a, so that the patient identity confirmation device 70 is self powered. In accordance with another aspect of the present invention, the patient identity confirmation device 70 can receive power from the mobile computer through the connection 56.


In accordance with one aspect of the present invention, the patient identity confirmation device 70 includes a camera 78 for capturing an image of the patient that is transmitted to the mobile computer 50. The camera 78 is electrically connected to the control unit 70a. The control unit 70a controls the activation of the camera 78 once the control unit 70a detected that a circuit path is complete, which indicates that the patient 60 is receiving the medication. More specifically, the patient 60 holds the patient identity confirmation device 70 using at least one of the contact points 72 and 74 to create a physical connection between the patient identity confirmation device 70 and the patient 60 at one of the limbs 62 and 64, e.g., right and left thumbs. As the patient 60 holds the patient identity confirmation device 70 and the syringe 30 comes into contact with the patient 60, then a circuit is completed. More specifically, the contact points 36 come into contact with the skin of the patient 60. The contact points 36 are electrically coupled to the tag 32 and the tag 32 is electrically coupled to the sleeve 34. The sleeve 34 is electrically coupled to the mobile computer 50 and the mobile computer 50 is electrically coupled to the patient identity confirmation device 70. Thus, a complete circuit is formed through the patient 60 once the patient hold the patient identity confirmation device 70 and the needle of the syringe 30 comes into contact with the skin of the patient 60.


As indicated above the contact points 72 and 74 can detect physiological parameters of the patient through the physical contact, including a change in heart rate, which is typical when the needle of the syringe 30 pierces the skin of patient 60. This change in physiological parameter of the patient 60 can be a trigger that is used by the control unit 70a to activate the camera to capture an image of the patient 60. The information associated with the time and date of delivery as well as the image of the patient 60 is sent to the mobile computer 50. The mobile computer 50 can record the delivery of the medication to the patient 60. Additionally, the mobile computer 50 can scan or interrogate the tag 32 to confirm the dose and type of medication delivered. Thereafter, the zinc-based layer of the tag 32 expires and the tag 32 cannot be used again. In accordance with another aspect of the present invention, the syringe 30 may be a single use syringe such that once the plunger is depressed, it cannot be retracted or extracted.


In various aspects the identifiable tags 22, 32, similar to an ingestible event marker or an ionic emission module (IEM), may be implemented in accordance with the system 120 shown in FIG. 4. The system 120 can be used in association with any medication product, as mentioned above, to determine the origin of the medication and to confirm that at least one of the right type and the right dosage of medication was delivered to the patient and in some aspects to determine when a patient takes the pharmaceutical product. The scope of the present disclosure, however, is not limited by the environment and the product that is used with the system 120. For example, the system may be activated either in wireless mode, in galvanic mode by placing the system 120 within a capsule and the placing the capsule within the conducting fluid, or a combination thereof, or exposing the system 120 to air. Once placed in a conducting fluid, for example, the capsule would dissolve over a period of time and release the system 120 into the conducting fluid. Thus, in one aspect, the capsule would contain the system 120 and no product. Such a capsule may then be used in any environment where a conducting fluid is present and with any product. For example, the capsule may be dropped into a container filled with jet fuel, salt water, tomato sauce, motor oil, or any similar product. Additionally, the capsule containing the system 120 may be ingested at the same time that any pharmaceutical product is ingested in order to record the occurrence of the event, such as when the product was taken.


In the specific example of the system 120 combined with a medication or pharmaceutical product, as the product or pill is ingested, or exposed to air, the system 120 is activated in galvanic mode. The system 120 controls conductance to produce a unique current signature that is detected, thereby signifying that the pharmaceutical product has been taken. When activated in wireless mode, the system controls modulation of capacitive plates to produce a unique voltage signature associated with the system 120 that is detected.


In one aspect, the system 120 includes a framework 122. The framework 122 is a chassis for the system 120 and multiple components are attached to, deposited upon, or secured to the framework 122. In this aspect of the system 120, a digestible material 124 is physically associated with the framework 122. The material 124 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework all of which may be referred to herein as “deposit” with respect to the framework 122. The material 124 is deposited on one side of the framework 122. The materials of interest that can be used as material 124 include, but are not limited to: Cu, CuCl, or Cul. The material 124 is deposited by physical vapor deposition, electrodeposition, or plasma deposition, among other protocols. The material 124 may be from about 0.05 to about 500 μm thick, such as from about 5 to about 100 μm thick. The shape is controlled by shadow mask deposition, or photolithography and etching. Additionally, even though only one region is shown for depositing the material, each system 120 may contain two or more electrically unique regions where the material 124 may be deposited, as desired.


At a different side, which is the opposite side as shown in FIG. 4, another digestible material 126 is deposited, such that the materials 124 and 126 are dissimilar and insulated from each other. Although not shown, the different side selected may be the side next to the side selected for the material 124. The scope of the present disclosure is not limited by the side selected and the term “different side” can mean any of the multiple sides that are different from the first selected side. In various aspects, the dissimilar material may be located at different positions on a same side. Furthermore, although the shape of the system is shown as a square, the shape may be any geometrically suitable shape. The materials 124 and 126 are selected such that they produce a voltage potential difference when the system 120 is in contact with conducting liquid, such as body fluids. The materials of interest for material 126 include, but are not limited to: Mg, Zn, or other electronegative metals. As indicated above with respect to the material 124, the material 126 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework. Also, an adhesion layer may be necessary to help the material 126 (as well as material 124 when needed) to adhere to the framework 122. Typical adhesion layers for the material 126 are Ti, TiW, Cr or similar material. Anode material and the adhesion layer may be deposited by physical vapor deposition, electrodeposition or plasma deposition. The material 126 may be from about 0.05 to about 500 μm thick, such as from about 5 to about 100 μm thick. However, the scope of the present disclosure is not limited by the thickness of any of the materials nor by the type of process used to deposit or secure the materials to the framework 122.


According to the disclosure set forth, the materials 124 and 126 can be any pair of materials with different electrochemical potentials. Additionally, in the embodiments wherein the system 120 is used in-vivo, the materials 124 and 126 may be vitamins that can be absorbed. More specifically, the materials 124 and 126 can be made of any two materials appropriate for the environment in which the system 120 will be operating. For example, when used with an ingestible product, the materials 124 and 126 are any pair of materials with different electrochemical potentials that are ingestible. An illustrative example includes the instance when the system 120 is in contact with an ionic solution, such as stomach acids. Suitable materials are not restricted to metals, and in certain embodiments the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as CuCl or Cul). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.


Materials and pairings of interest include, but are not limited to, those reported in TABLE 1 below. In one embodiment, one or both of the metals may be doped with a non-metal, e.g., to enhance the voltage potential created between the materials as they come into contact with a conducting liquid. Non-metals that may be used as doping agents in certain embodiments include, but are not limited to: sulfur, iodine, and the like. In another embodiment, the materials are copper iodine (Cul) as the anode and magnesium (Mg) as the cathode. Aspects of the present disclosure use electrode materials that are not harmful to the human body.












TABLE 1







Anode
Cathode


















Metals
Magnesium, Zinc




Sodium (†),



Lithium (†) Iron


Salts

Copper salts: iodide, chloride, bromide,




sulfate, formate, (other anions possible)




Fe3+ salts: e.g. orthophosphate,




pyrophosphate, (other anions possible)




Oxygen (††) on platinum, gold or other




catalytic surfaces


Intercalation
Graphite with Li,
Vanadium oxide Manganese oxide


compounds
K, Ca, Na, Mg









Thus, when the system 120 is in contact with the conducting fluid, a current path is formed through the conducting fluid between the dissimilar materials 124 and 126. A control device 128 is secured to the framework 122 and electrically coupled to the materials 124 and 126. The control device 128 includes electronic circuitry, for example control logic that is capable of controlling and altering the conductance between the materials 124 and 126.


The voltage potential created between the dissimilar materials 124 and 126 provides the power for operating the system as well as produces the current flow through the conducting fluid and the system 120. In one aspect, the system 120 operates in direct current mode. In an alternative aspect, the system 120 controls the direction of the current so that the direction of current is reversed in a cyclic manner, similar to alternating current. As the system reaches the conducting fluid or the electrolyte, where the fluid or electrolyte component is provided by a physiological fluid, e.g., stomach acid, the path for current flow between the dissimilar materials 124 and 126 is completed external to the system 120; the current path through the system 120 is controlled by the control device 128. Completion of the current path allows for the current to flow and in turn a receiver, not shown, can detect the presence of the current and recognize that the system 120 has been activate and the desired event is occurring or has occurred.


In one embodiment, the two dissimilar materials 124 and 126 are similar in function to the two electrodes needed for a direct current power source, such as a battery. The conducting liquid acts as the electrolyte needed to complete the power source. The completed power source described is defined by the physical chemical reaction between the dissimilar materials 124 and 126 of the system 120 and the surrounding fluids of the body. The completed power source may be viewed as a power source that exploits reverse electrolysis in an ionic or a conduction solution such as gastric fluid, blood, or other bodily fluids and some tissues. Additionally, the environment may be something other than a body and the liquid may be any conducting liquid. For example, the conducting fluid may be salt water or a metallic based paint.


In certain aspects, the two dissimilar materials 124 and 126 are shielded from the surrounding environment by an additional layer of material. Accordingly, when the shield is dissolved and the two dissimilar materials 124, 126 are exposed to the target site, a voltage potential is generated.


In certain aspects, the complete power source or supply is one that is made up of active electrode materials, electrolytes, and inactive materials, such as current collectors, packaging. The active materials are any pair of materials with different electrochemical potentials. Suitable materials are not restricted to metals, and in certain embodiments the paired materials are chosen from metals and non-metals, e.g., a pair made up of a metal (such as Mg) and a salt (such as Cul). With respect to the active electrode materials, any pairing of substances—metals, salts, or intercalation compounds—with suitably different electrochemical potentials (voltage) and low interfacial resistance are suitable.


A variety of different materials may be employed as the materials that form the electrodes. In certain embodiments, electrode materials are chosen to provide for a voltage upon contact with the target physiological site, e.g., the stomach, sufficient to drive the system of the identifier. In certain embodiments, the voltage provided by the electrode materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1.0 volts or higher, where in certain embodiments, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.


Referring still to FIG. 4, the dissimilar materials 124 and 126 provide the voltage potential to activate the control device 128. Once the control device 128 is activated or powered up, the control device 128 can alter conductance between the first and second materials 124 and 126 in a unique manner. By altering the conductance between the first and second materials 124 and 126, the control device 128 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 120. This produces a unique current signature that can be detected and measured by a receiver (not shown), which can be positioned internal or external to the body. The receiver is disclosed in greater detail in U.S. patent application Ser. No. 12/673,326 entitled BODY-ASSOCIATED RECEIVER AND METHOD filed on Dec. 15, 2009, and published as 2010-0312188 A1 dated Dec. 9, 2010 which is incorporated herein by reference in its entirety. In addition to controlling the magnitude of the current path between the materials, non-conducting materials, membrane, or “skirt” are used to increase the “length” of the current path and, hence, act to boost the conductance path, as disclosed in the U.S. patent application Ser. No. 12/238,345 entitled, “In-Body Device with Virtual Dipole Signal Amplification” filed Sep. 25, 2008, the entire content of which is incorporated herein by reference. Alternatively, throughout the disclosure herein, the terms “non-conducting material,” “membrane,” and “skirt” are interchangeably used with the term “current path extender” without impacting the scope or the present embodiments and the claims herein. The skirt, shown in portion at 125 and 127, respectively, may be associated with, e.g., secured to, the framework 122. Various shapes and configurations for the skirt are contemplated as within the scope of the various aspects of the present invention. For example, the system 120 may be surrounded entirely or partially by the skirt and the skirt maybe positioned along a central axis of the system 120 or off-center relative to a central axis. Thus, the scope of the present invention as claimed herein is not limited by the shape or size of the skirt. Furthermore, in other embodiments, the dissimilar materials 124 and 126 may be separated by one skirt that is positioned in any defined region between the dissimilar materials 124 and 126.


The system 120 may be grounded through a ground contact. The system 120 also may include a sensor module. In operation, ion or current paths are established between the first material 124 to the second material 126 and through a conducting fluid in contact with the system 120. The voltage potential created between the first and second materials 124 and 126 is created through chemical reactions between the first and second materials 124/126 and the conducting fluid. In one aspect, the surface of the first material 124 is not planar, but rather an irregular surface. The irregular surface increases the surface area of the material and, hence, the area that comes in contact with the conducting fluid.


In one aspect, at the surface of the first material 124, there is chemical reaction between the material 124 and the surrounding conducting fluid such that mass is released into the conducting fluid. The term mass as used herein refers to protons and neutrons that form a substance. One example includes the instant where the material is CuCl and when in contact with the conducting fluid, CuCl becomes Cu (solid) and Cl— in solution. The flow of ions into the conduction fluid is via ion paths. In a similar manner, there is a chemical reaction between the second material 126 and the surrounding conducting fluid and ions are captured by the second material 126. The release of ions at the first material 124 and capture of ion by the second material 126 is collectively referred to as the ionic exchange.


The rate of ionic exchange and, hence the ionic emission rate or flow, is controlled by the control device 128. The control device 128 can increase or decrease the rate of ion flow by altering the conductance, which alters the impedance, between the first and second materials 124 and 126. Through controlling the ion exchange, the system 120 can encode information in the ionic exchange process. Thus, the system 120 uses ionic emission to encode information in the ionic exchange.


The control device 128 can vary the duration of a fixed ionic exchange rate or current flow magnitude while keeping the rate or magnitude near constant, similar to when the frequency is modulated and the amplitude is constant. Also, the control device 128 can vary the level of the ionic exchange rate or the magnitude of the current flow while keeping the duration near constant. Thus, using various combinations of changes in duration and altering the rate or magnitude, the control device 128 encodes information in the current flow or the ionic exchange. For example, the control device 128 may use, but is not limited to any of the following techniques namely, Binary Phase-Shift Keying (PSK), Frequency Modulation (FM), Amplitude Modulation (AM), On-Off Keying, and PSK with On-Off Keying.


Various aspects of the system 120 may comprise electronic components as part of the control device 128. Components that may be present include but are not limited to: logic and/or memory elements, an integrated circuit, an inductor, a resistor, and sensors for measuring various parameters. Each component may be secured to the framework and/or to another component. The components on the surface of the support may be laid out in any convenient configuration. Where two or more components are present on the surface of the solid support, interconnects may be provided.


The system 120 controls the conductance between the dissimilar materials and, hence, the rate of ionic exchange or the current flow. Through altering the conductance in a specific manner the system is capable of encoding information in the ionic exchange and the current signature. The ionic exchange or the current signature is used to uniquely identify the specific system. Additionally, the system 120 is capable of producing various different unique exchanges or signatures and, thus, provides additional information. For example, a second current signature based on a second conductance alteration pattern may be used to provide additional information, which information may be related to the physical environment. To further illustrate, a first current signature may be a very low current state that maintains an oscillator on the chip and a second current signature may be a current state at least a factor of ten higher than the current state associated with the first current signature.


Referring now back to FIG. 1, the mobile computer 50 is in communication with the data center 80. The data center 80 includes a database 82 and processing system 84.


Information associated with all patients, including identity and medication types and doses, are stored in the database 82. The processing system 84 receives information from the mobile computer 50 and accesses the information in the database 82 of the data center 80 to provide information to the care provider through the mobile computer 50. The mobile computer 50 can communicate information including a photo of the patient for identification, the type of medication available to the care provider, as well as confirmation of the type and dose of medication that the care provider selects and delivers to the patient 60. The mobile computer 50 can communicate with the data center 80 using any mode and frequency of communication that is available in at the site, such as wireless, G2, G3, real-time, periodically based on predetermined time delays, as well as store and forward at later time.



FIG. 1 illustrates one aspect of the mobile computer 50. In various aspects, the mobile computer 50 may comprise or be implemented by a wireless device.


The mobile computer 50 generally may comprise various physical or logical elements implemented as hardware, software, or any combination thereof, as desired for a given set of design parameters or performance constraints. In various aspects, the physical or logical elements may be connected by one or more communications media. For example, communication media may comprise wired communication media, wireless communication media, or a combination of both, as desired for a given implementation.


As shown, the mobile computer 50 may comprise a display 58. The display 58 may be implemented using any type of visual interface such as a liquid crystal display (LCD).


As shown, the mobile computer 50 may comprise a memory 102. In various aspects, the memory 102 may comprise any machine-readable or computer-readable media capable of storing data, including both volatile and non-volatile memory. For example, memory may include read-only memory (ROM), random-access memory (RAM), dynamic RAM (DRAM), Double-Data-Rate DRAM (DDR-RAM), synchronous DRAM (SDRAM), static RAM (SRAM), programmable ROM (PROM), erasable programmable


ROM (EPROM), electrically erasable programmable ROM (EEPROM), flash memory (e.g., NOR or NAND flash memory), content addressable memory (CAM), polymer memory (e.g., ferroelectric polymer memory), phase-change memory (e.g., ovonic memory), ferroelectric memory, silicon-oxide-nitride-oxide-silicon (SONOS) memory, disk memory (e.g., floppy disk, hard drive, optical disk, magnetic disk), or card (e.g., magnetic card, optical card), or any other type of media suitable for storing information.


The mobile computer 50 may comprise a processor 100 such as a central processing unit (CPU). In various aspects, the processor 100 may be implemented as a general purpose processor, a chip multiprocessor (CMP), a dedicated processor, an embedded processor, a digital signal processor (DSP), a network processor, a media processor, an input/output (I/O) processor, a media access control (MAC) processor, a radio baseband processor, a co-processor, a microprocessor such as a complex instruction set computer (CISC) microprocessor, a reduced instruction set computing (RISC) microprocessor, and/or a very long instruction word (VLIW) microprocessor, or other processing device. The processor 510 also may be implemented by a controller, a microcontroller, an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), a programmable logic device (PLD), and so forth.


In various aspects, the processor 100 may be arranged to run an operating system (OS) and various mobile applications. Examples of an OS include, for example, operating systems generally known under the trade name of Microsoft Windows OS, and any other proprietary or open source OS. Examples of mobile applications include, for example, a telephone application, a camera (e.g., digital camera, video camera) application, a browser application, a multimedia player application, a gaming application, a messaging application (e.g., e-mail, short message, multimedia), a viewer application, and so forth.


In various aspects, the processor 100 may be arranged to receive information through a communications interface 104. The communications interface 104 may comprises any suitable hardware, software, or combination of hardware and software that is capable of coupling the mobile computer 50 to one or more networks and/or devices, such as the pill 20, the tag 22, the device 40, interrogation unit 46, the patient identity confirmation device 70, the tag 32, the sleeve 34, and/or the data center 80, among other devices. The communications interface 104 may be arranged to operate with any suitable technique for controlling information signals using a desired set of communications protocols, services or operating procedures. The communications interface 104 may include the appropriate physical connectors to connect with a corresponding communications medium, whether wired or wireless.


Vehicles of communication include a network. In various aspects, the network may comprise local area networks (LAN) as well as wide area networks (WAN) including without limitation Internet, wired channels, wireless channels, communication devices including telephones, computers, wire, radio, optical or other electromagnetic channels, and combinations thereof, including other devices and/or components capable of/associated with communicating data. For example, the communication environments include in-body communications, various devices, various modes of communications such as wireless communications, wired communications, and combinations of the same.


Wireless communication modes include any mode of communication between points that utilizes, at least in part, wireless technology including various protocols and combinations of protocols associated with wireless transmission, data, and devices. The points include, for example, wireless devices such as wireless headsets, audio and multimedia devices and equipment, such as audio players and multimedia players, telephones, including mobile telephones and cordless telephones, and computers and computer-related devices and components, such as printers.


Wired communication modes include any mode of communication between points that utilizes wired technology including various protocols and combinations of protocols associated with wired transmission, data, and devices. The points include, for example, devices such as audio and multimedia devices and equipment, such as audio players and multimedia players, telephones, including mobile telephones and cordless telephones, and computers and computer-related devices and components, such as printers.


Accordingly, in various aspects, the communications interface 104 may comprise one or more interfaces such as, for example, a wireless communications interface, a wired communications interface, a network interface, a transmit interface, a receive interface, a media interface, a system interface, a component interface, a switching interface, a chip interface, a controller, and so forth. When implemented by a wireless device or within wireless system, for example, the mobile computer 50 may include a wireless interface comprising one or more antennas, transmitters, receivers, transceivers, amplifiers, filters, control logic, and so forth.


In various implementations, the described aspects may communicate over wireless shared media in accordance with a number of wireless protocols. Examples of wireless protocols may include various wireless local area network (WLAN) protocols, including the Institute of Electrical and Electronics Engineers (IEEE) 802.xx series of protocols, such as IEEE 802.11a/b/g/n, IEEE 802.16, IEEE 802.20, and so forth. Other examples of wireless protocols may include various wireless wide area network (WWAN) protocols, such as GSM cellular radiotelephone system protocols with GPRS, CDMA cellular radiotelephone communication systems with 1xRTT, EDGE systems, EV-DO systems, EV-DV systems, HSDPA systems, and so forth. Further examples of wireless protocols may include wireless personal area network (PAN) protocols, such as an Infrared protocol, a protocol from the Bluetooth Special Interest Group (SIG) series of protocols, including Bluetooth Specification versions v1.0, v1.1, v1.2, v2.0, v2.0 with Enhanced Data Rate (EDR), as well as one or more Bluetooth Profiles, and so forth. Yet another example of wireless protocols may include near-field communication techniques and protocols, such as electro-magnetic induction (EMI) techniques. An example of EMI techniques may include passive or active radio-frequency identification (RFID) protocols and devices. Other suitable protocols may include Ultra Wide Band (UWB), Digital Office (DO), Digital Home, Trusted Platform Module (TPM), ZigBee, and so forth.


In various implementations, the described aspects may comprise part of a cellular communication system. Examples of cellular communication systems may include CDMA cellular radiotelephone communication systems, GSM cellular radiotelephone systems, North American Digital Cellular (NADC) cellular radiotelephone systems, Time Division Multiple Access (TDMA) cellular radiotelephone systems, Extended-TDMA (E-TDMA) cellular radiotelephone systems, Narrowband Advanced Mobile Phone Service (NAMPS) cellular radiotelephone systems, third generation (3G) systems such as WCDMA, CDMA-2000, UMTS cellular radiotelephone systems compliant with the Third-Generation Partnership Project (3GPP), and so forth.


In various aspects, the mobile computer 50 includes the functionality to wirelessly receive and/or wirelessly transmit data, e.g., physiologic data.


Further, in various aspects, the mobile computer 50 may incorporate and/or be associated with, e.g., communicate with, various devices. Such devices may generate, receive, and/or communicate data, e.g., physiologic data. The devices include, for example, “intelligent” devices such as gaming devices, e.g., electronic slot machines, handheld electronic games, electronic components associated with games and recreational activities.


The mobile computer 50 may be implemented as a mobile telephone. For example, the mobile computer 50 may be implemented as a short-range, portable electronic device used for mobile voice or data communication over a network of specialized cell site base stations. The mobile telephone is sometimes known as or referred to as “mobile,” “wireless,” “cellular phone,” “cell phone,” or “hand phone (HP).”


In addition to the standard voice function of a telephone, various aspects of mobile telephones may support many additional services and accessories such as short message service (SMS) for text messaging, email, packet switching for access to the Internet, java gaming, wireless, e.g., short range data/voice communications, infrared, camera with video recorder, and multimedia messaging system (MMS) for sending and receiving photos and video. Some aspects of mobile telephones connect to a cellular network of base stations (cell sites), which is, in turn, interconnected to the public switched telephone network (PSTN) or satellite communications in the case of satellite phones. Various aspects of mobile telephones can connect to the Internet, at least a portion of which can be navigated using the mobile telephones.


Some embodiments may be implemented, for example, using a machine-readable medium or article which may store an instruction or a set of instructions that, if executed by a machine, may cause the machine to perform a method and/or operations in accordance with the embodiments. Such a machine may include, for example, any suitable processing platform, computing platform, computing device, processing device, computing system, processing system, computer, processor, or the like, and may be implemented using any suitable combination of hardware and/or software. The machine-readable medium or article may include, for example, any suitable type of memory unit, memory device, memory article, memory medium, storage device, storage article, storage medium and/or storage unit, for example, memory, removable or non-removable media, erasable or non-erasable media, writeable or re-writeable media, digital or analog media, hard disk, floppy disk, Compact Disk Read Only Memory (CD-ROM), Compact Disk Recordable (CD-R), Compact Disk Rewriteable (CD-RW), optical disk, magnetic media, magneto-optical media, removable memory cards or disks, various types of Digital Versatile Disk (DVD), a tape, a cassette, or the like. The instructions may include any suitable type of code, such as source code, compiled code, interpreted code, executable code, static code, dynamic code, and the like. The instructions may be implemented using any suitable high-level, low-level, object-oriented, visual, compiled and/or interpreted programming language, such as C,


C++, Java, BASIC, Perl, Matlab, Pascal, Visual BASIC, assembly language, machine code, and so forth.


It is to be understood that this invention is not limited to particular embodiments or aspects described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.


Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.


All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.


It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.


Unless specifically stated otherwise, it may be appreciated that terms such as “processing,” “computing,” “calculating,” “determining,” or the like, refer to the action and/or processes of a computer or computing system, or similar electronic computing device, that manipulates and/or transforms data represented as physical quantities (e.g., electronic) within the computing system's registers and/or memories into other data similarly represented as physical quantities within the computing system's memories, registers or other such information storage, transmission or display devices.


Numerous specific details have been set forth herein to provide a thorough understanding of the embodiments. It will be understood by those skilled in the art, however, that the embodiments may be practiced without these specific details. In other instances, well-known operations, components and circuits have not been described in detail so as not to obscure the embodiments. It can be appreciated that the specific structural and functional details disclosed herein may be representative and do not necessarily limit the scope of the embodiments.


Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the scope of the appended claims.


Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

Claims
  • 1. A computer system comprising: an interrogation device operative to read a unique identity from a tag comprising circuitry, the tag secured to a pill of a medication;wherein the pill is configured to transmit a signal upon being ingested by a patient and comprises: a first material;a second material insulated from the first material; anda control circuit electrically coupled to each of the first material and the second material;wherein the first material and the second material are configured to generate a voltage potential difference as a result of being in contact with a conducting liquid;wherein the control circuit is configured to be activated by the voltage potential difference and configured to alter a conductance between the first material and the second material to generate the signal;a patient interface device configured to detect biometric information identifying the patient via physical contact therewith; anda processor operative to: receive, from the interrogation device, the unique identity of the tag, wherein the unique identity is associated with at least one of an amount of the medication and a type of the medication;receive, from the patient interface device, the biometric information;query a database to confirm that the biometric information identifying the patient is associated with the amount of the medication and the type of the medication; andrecord administration of the medication upon detection of the signal.
  • 2. The computer system of claim 1, wherein the processor is operative to receive medical information regarding a correct amount of the medication and a correct type of medication for the patient.
  • 3. The computer system of claim 1, wherein the processor is operative to communicate with a datacenter to at least one of retrieve medical information about the patient or provide information related to the medication to be administered to the patient.
  • 4. The computer system of claim 3, wherein the processor is operative to: communicate with at least one of a database or a processing system at the datacenter;transmit information to the processing system; andreceive information from the processing system, wherein the processing system is operative to access the information in the database of the datacenter and provide the information to the patient through a computer.
  • 5. The computer system of claim 1, wherein the processor is operative to validate at least one of a correct type of the medication and a correct amount of the medication selected by a care provider prior to dispensing the medication to the patient.
  • 6. The computer system of claim 1, wherein the processor is operative to: communicate with a memory of the interrogation device; andreceive the unique identity of the tag stored in the memory of the interrogation device.
  • 7. The computer system of claim 1, wherein the processor is operative to identify the patient based on the biometric information.
  • 8. The computer system of claim 1, wherein the processor is operative to receive an image of the patient captured by a camera on the patient interface device.
  • 9. The computer system of claim 1, further comprising a display configured to provide patient information associated with the patient, wherein the patient information comprises at least one of an image of the patient, a medical history of the patient, or a next type and dose of medication to deliver to the patient.
  • 10. A computer-implemented method comprising: receiving, by a processor, a unique identity from a tag comprising circuitry secured to a pill of a medication;wherein the unique identity is associated with at least one of an amount of the medication and a type of the medication;wherein the pill comprises: a first material;a second material insulated from the first material; anda control circuit electrically coupled to each of the first material and the second material;wherein the first material and the second material are configured to generate a voltage potential difference as a result of being in contact with a conducting liquid; andwherein the control circuit is configured to be activated by the voltage potential difference and configured to alter a conductance between the first material and the second material to generate the signal;receiving, by the processor, biometric information identifying a patient via physical contact with a patient interface device;receiving the signal transmitted by the pill upon the pill being ingested by a patient;querying a database to confirm that the biometric information identifying the patient is associated with the amount of the medication and the type of the medication; andrecording administration of the medication upon detection of the signal.
  • 11. The computer-implemented method of claim 10, further comprising at least one of: retrieving, by the processor, medical information about the patient from a datacenter database; andproviding, by the processor, information related to the medication to be administered to the patient.
  • 12. The computer-implemented method of claim 11, further comprising: transmitting, by the processor, information to a processing system; andreceiving, by the processor, information from the processing system, wherein the processing system is operative to access the information in the datacenter database and provide the information to the patient through a computer.
  • 13. The computer-implemented method of claim 10, further comprising: validating, by the processor, at least one of a correct type of the medication and a correct amount of the medication selected by a care provider prior to dispensing the medication to the patient.
  • 14. The computer-implemented method of claim 10, wherein the unique identity includes an origin of the medication.
  • 15. The computer-implemented method of claim 10, further comprising: communicating, by the processor, with a memory of an interrogation unit, the interrogation unit configured to receive the unique identity of the tag; andreceiving, by the processor, the unique identity of the tag stored in the memory of the interrogation unit.
  • 16. The computer-implemented method of claim 10, wherein the processor is operative to identify the patient based on the biometric information.
  • 17. The computer-implemented method of claim 10, further comprising: receiving, by the processor, an image of the patient captured by a camera on the patient interface device.
  • 18. The computer-implemented method of claim 10, further comprising: displaying, on a display coupled to the processor, patient information associated with the patient, wherein the patient information comprises at least one of an image of the patient, medical history of the patient, or a next type and dose of medication to deliver to the patient.
  • 19. A computer system comprising: an interrogation device operative to read a unique identity from a tag comprising circuitry, the tag secured to a syringe containing a medication;wherein the syringe is configured to transmit a signal upon contacting a patient and comprises electrical contacts configured to cause a circuit to transmit a signal upon the electrical contacts contacting the patient;a patient interface device configured to detect biometric information identifying the patient via physical contact therewith; anda processor operative to: receive, from the interrogation device, the unique identity of the tag, wherein the unique identity is associated with at least one of an amount of the medication and a type of the medication;receive, from the patient interface device, the biometric information;query a database to confirm that the biometric information identifying the patient is associated with the amount of the medication and the type of the medication; andrecord administration of the medication upon detection of the signal.
  • 20. The computer system of claim 19, wherein the syringe comprises a needle and wherein the needle comprises at least one contact point coupled to the tag.
  • 21. A computer-implemented method comprising: receiving, by a processor, a unique identity from a tag comprising circuitry secured to a syringe of a medication;wherein the unique identity is associated with at least one of an amount of the medication and a type of the medication;wherein the syringe comprises electrical contacts configured to cause a circuit to transmit a signal upon the electrical contacts contacting a patient:receiving, by the processor, biometric information identifying a patient via physical contact with a patient interface device;receiving the signal transmitted by the syringe upon the syringe contacting the patient;querying a database to confirm that the biometric information identifying the patient is associated with the amount of the medication and the type of the medication; andrecording administration of the medication upon detection of the signal.
  • 22. The computer-implemented method of claim 21, wherein the syringe comprises a safety component which is activated upon exposure to air.
  • 23. The computer-implemented method of claim 21, wherein the syringe comprises a needle and the needle comprises at least one contact point coupled to the tag.
CROSS REFERENCE To RELATED APPLICATIONS

The present application is a U.S. national phase application filed under 35 U.S.C. § 371 of International Patent Application No. PCT/US2011/037236, entitled “TRACKING AND DELIVERY CONFIRMATION OF PHARMACEUTICAL PRODUCTS,” filed May 19, 2011, which application claims the benefit under 35 U.S.C. § 119 (e) of U.S. Provisional Patent Application No. 61/346,035 entitled “TRACKING AND DELIVERY CONFIRMATION OF PHARMACEUTICAL PRODUCTS” and filed on May 19, 2010, which applications are hereby incorporated by reference in their entireties.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2011/037236 5/19/2011 WO 00 11/19/2012
Publishing Document Publishing Date Country Kind
WO2011/146767 11/24/2011 WO A
US Referenced Citations (1107)
Number Name Date Kind
3218638 Honig Nov 1965 A
3345989 Reynolds Oct 1967 A
3353539 Preston Nov 1967 A
3409721 Applezweig Nov 1968 A
3419736 Walsh Dec 1968 A
3589943 Grubb et al. Jun 1971 A
3607788 Adolph Sep 1971 A
3628669 McKinnis et al. Dec 1971 A
3642008 Bolduc Feb 1972 A
3679480 Brown et al. Jul 1972 A
3682160 Murata Aug 1972 A
3719183 Schwartz Mar 1973 A
3727616 Lenzkes Apr 1973 A
3799802 Schneble, Jr. et al. Mar 1974 A
3825016 Lale et al. Jul 1974 A
3828766 Krasnow Aug 1974 A
3837339 Aisenberg et al. Sep 1974 A
3893111 Cotter Jul 1975 A
3944064 Bashaw et al. Mar 1976 A
3967202 Batz Jun 1976 A
3989050 Buchalter Nov 1976 A
4017856 Wiegand Apr 1977 A
4055178 Harrigan Oct 1977 A
4062750 Butler Dec 1977 A
4077397 Ellis Mar 1978 A
4077398 Ellis Mar 1978 A
4082087 Howson Apr 1978 A
4090752 Long May 1978 A
4105023 Merchese et al. Aug 1978 A
4106348 Auphan Aug 1978 A
4129125 Lester Dec 1978 A
4133730 DuBois et al. Jan 1979 A
4141349 Ory et al. Feb 1979 A
4166453 McClelland Sep 1979 A
4239046 Ong Dec 1980 A
4251795 Shibasaki et al. Feb 1981 A
4269189 Abraham May 1981 A
4281664 Duggan Aug 1981 A
4331654 Morris May 1982 A
4345588 Widder et al. Aug 1982 A
4418697 Tama Dec 1983 A
4425117 Hugemann Jan 1984 A
4439196 Higuchi Mar 1984 A
4494950 Fischell Jan 1985 A
4526474 Simon Jul 1985 A
4547391 Jenkins Oct 1985 A
4559950 Vaughan Dec 1985 A
4564363 Bagnall et al. Jan 1986 A
4578061 Lemelson Mar 1986 A
4618533 Steuck Oct 1986 A
4635641 Hoffman Jan 1987 A
D377983 Sabri et al. Feb 1987 S
4654165 Eisenber Mar 1987 A
4663250 Ong et al. May 1987 A
4669479 Dunseath Jun 1987 A
4681111 Silvian Jul 1987 A
4687660 Baker et al. Aug 1987 A
4725997 Urquhart et al. Feb 1988 A
4749575 Rotman et al. Jun 1988 A
4763659 Dunseath Aug 1988 A
4767627 Caldwell et al. Aug 1988 A
4784162 Ricks Nov 1988 A
4793825 Benjamin et al. Dec 1988 A
4809705 Ascher Mar 1989 A
4835373 Adams et al. May 1989 A
4844076 Lesho Jul 1989 A
4871974 Davis et al. Oct 1989 A
4876093 Theeuwes et al. Oct 1989 A
4896261 Nolan Jan 1990 A
4975230 Pinkhasov Dec 1990 A
4987897 Funke Jan 1991 A
5000957 Eckenhoff et al. Mar 1991 A
5016634 Vock et al. May 1991 A
5079006 Urguhart Jan 1992 A
5167626 Casper Dec 1992 A
5176626 Soehendra Jan 1993 A
5179578 Ishizu Jan 1993 A
5245332 Katzenstein et al. Sep 1993 A
5261402 DiSabito Nov 1993 A
5263481 Axelgaard et al. Nov 1993 A
5276710 Iwasaki Jan 1994 A
5279607 Schentag et al. Jan 1994 A
5281287 Lloyd Jan 1994 A
5283136 Peled et al. Feb 1994 A
5288564 Klein Feb 1994 A
5305745 Zacouto Apr 1994 A
5318557 Gross Jun 1994 A
5394882 Mawhinney Mar 1995 A
5395366 D'Andrea et al. Mar 1995 A
5411535 Fujii et al. May 1995 A
5412372 Parkhurst et al. May 1995 A
5428961 Sakakibara Jul 1995 A
5436091 Shackle et al. Jul 1995 A
5443461 Atkinson et al. Aug 1995 A
5443843 Curatolo et al. Aug 1995 A
5458141 Neil et al. Oct 1995 A
5468222 Altchuler Nov 1995 A
5485841 Watkin et al. Jan 1996 A
5511548 Riazzi et al. Apr 1996 A
5538007 Gorman Jul 1996 A
5551953 Lattin Sep 1996 A
5567210 Bates et al. Oct 1996 A
5596302 Mastrocola et al. Jan 1997 A
5600548 Nguyen et al. Feb 1997 A
5634466 Gruner Jun 1997 A
5634468 Platt Jun 1997 A
5638406 Sogabe Jun 1997 A
5645063 Straka et al. Jul 1997 A
5705189 Lehmann et al. Jan 1998 A
5738708 Peachey et al. Apr 1998 A
5740811 Hedberg Apr 1998 A
5757326 Koyama et al. May 1998 A
5792048 Schaefer Aug 1998 A
5802467 Salazar Sep 1998 A
5833716 Bar-Or Nov 1998 A
5836474 Wessberg Nov 1998 A
5845265 Woolston Dec 1998 A
5862803 Besson Jan 1999 A
5862808 Albarello Jan 1999 A
5868136 Fox Feb 1999 A
5914701 Gersheneld et al. Jun 1999 A
5917346 Gord Jun 1999 A
5921925 Cartmell et al. Jul 1999 A
5925030 Gross et al. Jul 1999 A
5925066 Kroll et al. Jul 1999 A
5957854 Besson et al. Sep 1999 A
5965629 Jung et al. Oct 1999 A
5974124 Schlueter, Jr. et al. Oct 1999 A
5981166 Mandecki Nov 1999 A
5999846 Pardey et al. Dec 1999 A
6009350 Renken Dec 1999 A
6023631 Cartmell et al. Feb 2000 A
6038464 Axelgaard et al. Mar 2000 A
6042710 Dubrow Mar 2000 A
6047203 Sackner Apr 2000 A
6076016 Feierbach et al. Jun 2000 A
6081734 Batz Jun 2000 A
6083248 Thompson Jul 2000 A
6090489 Hayakawa et al. Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6095985 Raymond et al. Aug 2000 A
6099482 Brune et al. Aug 2000 A
6115636 Ryan Sep 2000 A
6117077 Del Mar et al. Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6141592 Pauly Oct 2000 A
6149940 Maggi et al. Nov 2000 A
6200265 Walsh et al. Mar 2001 B1
6204764 Maloney Mar 2001 B1
6206702 Hayden et al. Mar 2001 B1
6217744 Crosby Mar 2001 B1
6231593 Meserol May 2001 B1
6245057 Sieben et al. Jun 2001 B1
6269058 Yamanoi et al. Jul 2001 B1
6285897 Kilcoyne et al. Sep 2001 B1
6287252 Lugo Sep 2001 B1
6288629 Cofino et al. Sep 2001 B1
6289238 Besson et al. Sep 2001 B1
6315719 Rode et al. Nov 2001 B1
6342774 Kreisinger et al. Jan 2002 B1
6344824 Takasugi et al. Feb 2002 B1
6358202 Arent Mar 2002 B1
6364834 Reuss Apr 2002 B1
6366206 Ishikawa et al. Apr 2002 B1
6368190 Easter et al. Apr 2002 B1
6371927 Brune Apr 2002 B1
6374670 Spelman Apr 2002 B1
6380858 Yarin et al. Apr 2002 B1
6390088 Noehl et al. May 2002 B1
6394953 Devlin et al. May 2002 B1
6394997 Lemelson May 2002 B1
6411567 Niemiec et al. Jun 2002 B1
6426863 Munshi Jul 2002 B1
6432292 Pinto et al. Aug 2002 B1
6440069 Raymond et al. Aug 2002 B1
6441747 Khair Aug 2002 B1
6453199 Kobozev Sep 2002 B1
6477424 Thompson et al. Nov 2002 B1
6482156 Lliff Nov 2002 B2
6494829 New et al. Dec 2002 B1
6496705 Ng et al. Dec 2002 B1
6505077 Kast et al. Jan 2003 B1
6525996 Miyazawa Feb 2003 B1
6526315 Inagawa Feb 2003 B1
6531026 Takeichi et al. Mar 2003 B1
6540699 Smith Apr 2003 B1
6544174 West Apr 2003 B2
6564079 Cory May 2003 B1
6572636 Hagen et al. Jun 2003 B1
6574425 Weiss et al. Jun 2003 B1
6577893 Besson et al. Jun 2003 B1
6579231 Phipps Jun 2003 B1
6595929 Stivoric Jul 2003 B2
6599284 Faour et al. Jul 2003 B2
6605038 Teller Aug 2003 B1
6605046 Del Mar Aug 2003 B1
6609018 Cory Aug 2003 B2
6612984 Kerr Sep 2003 B1
6632175 Marshall Oct 2003 B1
6632216 Houzego et al. Oct 2003 B2
6635279 Kolter et al. Oct 2003 B2
6638231 Govari et al. Oct 2003 B2
6643541 Mok et al. Nov 2003 B2
6650718 Fujimura et al. Nov 2003 B1
6654638 Sweeney Nov 2003 B1
6663846 McCombs Dec 2003 B1
6673474 Yamamoto Jan 2004 B2
6679830 Kolarovic et al. Jan 2004 B2
6680923 Leon Jan 2004 B1
6683493 Fujimora et al. Jan 2004 B1
6689117 Sweeney et al. Feb 2004 B2
6694161 Mehrotra Feb 2004 B2
6704602 Berg et al. Mar 2004 B2
6720923 Hayward et al. Apr 2004 B1
6738671 Christophersom et al. May 2004 B2
6740033 Olejniczak et al. May 2004 B1
6745082 Axelgaard et al. Jun 2004 B2
6755783 Cosentino Jun 2004 B2
6757523 Fry Jun 2004 B2
6759968 Zierolf Jul 2004 B2
6771174 Broas Aug 2004 B2
6773429 Sheppard et al. Aug 2004 B2
6800060 Marshall Oct 2004 B2
6801137 Eggers et al. Oct 2004 B2
6804558 Haller et al. Oct 2004 B2
6814706 Barton et al. Nov 2004 B2
6822554 Vrijens et al. Nov 2004 B2
6836862 Erekson et al. Dec 2004 B1
6839659 Tarassenko et al. Jan 2005 B2
6840904 Goldberg Jan 2005 B2
6842636 Perrault Jan 2005 B2
6845272 Thomsen Jan 2005 B1
6864780 Doi Mar 2005 B2
6879810 Bouet Apr 2005 B2
6882881 Lesser et al. Apr 2005 B1
6897788 Khair et al. May 2005 B2
6909878 Haller Jun 2005 B2
6922592 Thompson et al. Jul 2005 B2
6928370 Anuzis et al. Aug 2005 B2
6929636 Von Alten Aug 2005 B1
6937150 Medema Aug 2005 B2
6939292 Mizuno Sep 2005 B2
6942616 Kerr Sep 2005 B2
6951536 Yokoi Oct 2005 B2
6957107 Rogers et al. Oct 2005 B2
6959929 Pugnet et al. Nov 2005 B2
6968153 Heinonen Nov 2005 B1
6987965 Ng et al. Jan 2006 B2
6990082 Zehavi et al. Jan 2006 B1
7002476 Rapchak Feb 2006 B2
7004395 Koenck Feb 2006 B2
7009634 Iddan et al. Mar 2006 B2
7009946 Kardach Mar 2006 B1
7013162 Gorsuch Mar 2006 B2
7016648 Haller Mar 2006 B2
7020508 Stivoric Mar 2006 B2
7023940 Nakamura et al. Apr 2006 B2
7024248 Penner et al. Apr 2006 B2
7031745 Shen Apr 2006 B2
7031857 Tarassenko et al. Apr 2006 B2
7039453 Mullick May 2006 B2
7044911 Drinan et al. May 2006 B2
7046649 Awater et al. May 2006 B2
7050419 Azenkot et al. May 2006 B2
7062308 Jackson Jun 2006 B1
7069062 Minotani et al. Jun 2006 B2
7076437 Levy Jul 2006 B1
7081693 Hamel et al. Jul 2006 B2
7091726 Sano et al. Aug 2006 B2
7118531 Krill Oct 2006 B2
7125382 Zhou et al. Oct 2006 B2
7127300 Mazar et al. Oct 2006 B2
7146228 Nielsen Dec 2006 B2
7146449 Do et al. Dec 2006 B2
7149581 Goedeke et al. Dec 2006 B2
7154071 Sattler et al. Dec 2006 B2
7155232 Godfrey et al. Dec 2006 B2
7160258 Imran Jan 2007 B2
7161484 Tsoukalis Jan 2007 B2
7164942 Avrahami Jan 2007 B2
7171166 Ng et al. Jan 2007 B2
7171177 Park et al. Jan 2007 B2
7171259 Rytky Jan 2007 B2
7176784 Gilbert et al. Feb 2007 B2
7187960 Abreu Mar 2007 B2
7188767 Penuela Mar 2007 B2
7194038 Inkinen Mar 2007 B1
7206630 Tarler Apr 2007 B1
7209790 Thompson et al. Apr 2007 B2
7215660 Perlman May 2007 B2
7215991 Besson May 2007 B2
7218967 Bergelson May 2007 B2
7231451 Law Jun 2007 B2
7243118 Lou Jul 2007 B2
7246521 Kim Jul 2007 B2
7249212 Do Jul 2007 B2
7252792 Perrault Aug 2007 B2
7253716 Lovoi et al. Aug 2007 B2
7261690 Teller Aug 2007 B2
7270633 Goscha Sep 2007 B1
7273454 Raymond et al. Sep 2007 B2
7285090 Stivoric et al. Oct 2007 B2
7289855 Nghiem Oct 2007 B2
7291014 Chung et al. Nov 2007 B2
7291497 Holmes Nov 2007 B2
7292139 Mazar et al. Nov 2007 B2
7294105 Islam Nov 2007 B1
7295877 Govari Nov 2007 B2
7311665 Hawthorne Dec 2007 B2
7313163 Liu Dec 2007 B2
7317378 Jarvis et al. Jan 2008 B2
7318808 Tarassenko et al. Jan 2008 B2
7336732 Wiss Feb 2008 B1
7336929 Yasuda Feb 2008 B2
7342895 Serpa Mar 2008 B2
7346380 Axelgaard et al. Mar 2008 B2
7349722 Witkowski et al. Mar 2008 B2
7352998 Palin Apr 2008 B2
7353258 Washburn Apr 2008 B2
7357891 Yang et al. Apr 2008 B2
7359674 Markki Apr 2008 B2
7366558 Virtanen et al. Apr 2008 B2
7366675 Walker et al. Apr 2008 B1
7368190 Heller et al. May 2008 B2
7368191 Andelman et al. May 2008 B2
7373196 Ryu et al. May 2008 B2
7375739 Robbins May 2008 B2
7376435 McGowan May 2008 B2
7382247 Welch et al. Jun 2008 B2
7382263 Danowski et al. Jun 2008 B2
7387607 Holt Jun 2008 B2
7388903 Godfrey et al. Jun 2008 B2
7389088 Kim Jun 2008 B2
7392015 Farlow Jun 2008 B1
7395106 Ryu et al. Jul 2008 B2
7396330 Banet Jul 2008 B2
7404968 Abrams et al. Jul 2008 B2
7413544 Kerr Aug 2008 B2
7414534 Kroll et al. Aug 2008 B1
7414543 Rye et al. Aug 2008 B2
7415242 Ngan Aug 2008 B1
7419468 Shimizu et al. Sep 2008 B2
7424268 Diener Sep 2008 B2
7424319 Muehlsteff Sep 2008 B2
7427266 Ayer et al. Sep 2008 B2
7433731 Matsumura et al. Oct 2008 B2
7449262 Christie et al. Nov 2008 B2
7462150 Bharmi Dec 2008 B1
7471665 Perlman Dec 2008 B2
7485093 Glukhovsky Feb 2009 B2
7485095 Shusterman Feb 2009 B2
7499674 Salokannel Mar 2009 B2
7502643 Farringdon et al. Mar 2009 B2
7505795 Lim et al. Mar 2009 B1
7508248 Yoshida Mar 2009 B2
7510121 Koenck Mar 2009 B2
7512448 Malick Mar 2009 B2
7512860 Miyazaki et al. Mar 2009 B2
7515043 Welch Apr 2009 B2
7519416 Sula et al. Apr 2009 B2
7523756 Minai Apr 2009 B2
7525426 Edelstein Apr 2009 B2
7539533 Tran May 2009 B2
7542878 Nanikashvili Jun 2009 B2
7547278 Miyazaki et al. Jun 2009 B2
7551590 Haller Jun 2009 B2
7554452 Cole Jun 2009 B2
7558620 Ishibashi Jul 2009 B2
7558622 Tran Jul 2009 B2
7558965 Wheeler et al. Jul 2009 B2
7575005 Mumford Aug 2009 B2
7614743 Geiger Nov 2009 B2
7616111 Covannon Nov 2009 B2
7616710 Kim et al. Nov 2009 B2
7617001 Penner et al. Nov 2009 B2
7639473 Hsu et al. Dec 2009 B2
7640802 King et al. Jan 2010 B2
7647112 Tracey Jan 2010 B2
7647185 Tarassenko et al. Jan 2010 B2
7653031 Godfrey et al. Jan 2010 B2
7668437 Yamada et al. Feb 2010 B1
7683761 Burghard et al. Feb 2010 B2
7672703 Yeo et al. Mar 2010 B2
7672714 Kuo Mar 2010 B2
7673679 Harrison et al. Mar 2010 B2
7678043 Gilad Mar 2010 B2
7689437 Teller et al. Mar 2010 B1
7689833 Lange Mar 2010 B2
7697994 VanDanacker et al. Apr 2010 B2
7712288 Ramasubramanian et al. May 2010 B2
7720036 Sadri May 2010 B2
7729776 Von Arx et al. Jun 2010 B2
7733224 Tran Jun 2010 B2
7736318 Costentino Jun 2010 B2
7747454 Bartfeld et al. Jun 2010 B2
7756587 Penner et al. Jul 2010 B2
7764996 Zhang et al. Jul 2010 B2
7779614 McGonagle et al. Aug 2010 B1
7797033 D'Andrea et al. Sep 2010 B2
7806852 Jurson Oct 2010 B1
7809399 Lu Oct 2010 B2
7811231 Jin et al. Oct 2010 B2
7844341 Von Arx et al. Nov 2010 B2
7857766 Lasater et al. Dec 2010 B2
7860731 Jackson et al. Dec 2010 B2
7871734 Hertz et al. Jan 2011 B2
7899526 Benditt et al. Mar 2011 B2
7904133 Gehman et al. Mar 2011 B2
D639437 Bishay et al. Jun 2011 S
8036731 Kimchy et al. Oct 2011 B2
8036748 Zdeblick et al. Oct 2011 B2
8060249 Bear et al. Nov 2011 B2
8073707 Teller et al. Dec 2011 B2
8083128 Dembo et al. Dec 2011 B2
8123576 Kim Feb 2012 B2
8135596 Jung et al. Mar 2012 B2
8142513 Shalon et al. Mar 2012 B2
8177611 Kang May 2012 B2
8180425 Selvitelli et al. May 2012 B2
8185191 Shapiro et al. May 2012 B1
8185646 Headley May 2012 B2
8200320 Kovacs Jun 2012 B2
8209018 Osorio et al. Jun 2012 B2
8214007 Baker et al. Jul 2012 B2
8224667 Miller et al. Jul 2012 B1
8238998 Park Aug 2012 B2
8249686 Libbus et al. Aug 2012 B2
8253586 Matak Aug 2012 B1
8254853 Rofougaran Aug 2012 B2
8258962 Robertson et al. Sep 2012 B2
8262394 Walker et al. Sep 2012 B2
8285356 Bly et al. Oct 2012 B2
8290574 Felid et al. Oct 2012 B2
8301232 Albert et al. Oct 2012 B2
8308640 Baldus et al. Nov 2012 B2
8314619 Takiguchi Nov 2012 B2
8315687 Cross et al. Nov 2012 B2
8343068 Najafi et al. Jan 2013 B2
8369936 Farringdon et al. Feb 2013 B2
8386009 Lindberg et al. Feb 2013 B2
8389003 Mintchev et al. Mar 2013 B2
8404275 Habboushe Mar 2013 B2
8440274 Wang May 2013 B2
8454528 Yuen et al. Jun 2013 B2
8514086 Harper et al. Aug 2013 B2
8542123 Robertson Sep 2013 B2
8545402 Hafezi et al. Oct 2013 B2
8564432 Covannon et al. Oct 2013 B2
8564627 Suzuki et al. Oct 2013 B2
8583227 Savage et al. Nov 2013 B2
8597186 Hafezi et al. Dec 2013 B2
8634838 Hellwig et al. Jan 2014 B2
8660645 Stevenson et al. Feb 2014 B2
8668643 Kinast Mar 2014 B2
8668645 Heller et al. Mar 2014 B2
8718193 Arne et al. May 2014 B2
8722085 McKinney et al. May 2014 B2
8771183 Sloan Jul 2014 B2
8810260 Zhou Aug 2014 B1
8810409 Robertson et al. Aug 2014 B2
8823510 Downey et al. Sep 2014 B2
8836513 Hafezi et al. Sep 2014 B2
8838217 Myr Sep 2014 B2
8868453 Zdeblick Oct 2014 B2
8908943 Berry et al. Dec 2014 B2
8926509 Magar et al. Jan 2015 B2
8932221 Colliou et al. Jan 2015 B2
8945005 Hafezi et al. Feb 2015 B2
8956287 Zdeblick et al. Feb 2015 B2
8956288 Hafezi et al. Feb 2015 B2
8966973 Milone Mar 2015 B1
8989837 Weinstein et al. Mar 2015 B2
9031658 Chiao et al. May 2015 B2
9047746 Euliano et al. Jun 2015 B1
9088168 Mach et al. Jul 2015 B2
9119918 Robertson et al. Sep 2015 B2
9125868 McKinney et al. Sep 2015 B2
9189941 Eschelman et al. Nov 2015 B2
9226663 Fei Jan 2016 B2
9226679 Balda Jan 2016 B2
9235683 Robertson et al. Jan 2016 B2
9258035 Robertson et al. Feb 2016 B2
9270025 Robertson et al. Feb 2016 B2
9277864 Yang et al. Mar 2016 B2
9278177 Edwards et al. Mar 2016 B2
9433371 Hafezi et al. Sep 2016 B2
9439582 Berkman et al. Sep 2016 B2
9439599 Thompson et al. Sep 2016 B2
9444503 Arne et al. Sep 2016 B2
9517012 Lane et al. Dec 2016 B2
9603550 Behzadi Mar 2017 B2
9883819 Jensen et al. Feb 2018 B2
20010027331 Thompson Oct 2001 A1
20010031071 Nichols et al. Oct 2001 A1
20010039503 Chan et al. Nov 2001 A1
20010044588 Mault Nov 2001 A1
20010051766 Gazdinski Dec 2001 A1
20010056262 Cabiri et al. Dec 2001 A1
20020002326 Causey et al. Jan 2002 A1
20020019586 Teller et al. Feb 2002 A1
20020026111 Ackerman Feb 2002 A1
20020032384 Raymond et al. Mar 2002 A1
20020032385 Raymond et al. Mar 2002 A1
20020040278 Anuzis et al. Apr 2002 A1
20020067270 Yarin et al. Jun 2002 A1
20020077620 Sweeney et al. Jun 2002 A1
20020128934 Shaer Sep 2002 A1
20020132226 Nair Sep 2002 A1
20020138009 Brockway et al. Sep 2002 A1
20020184415 Naghavi et al. Dec 2002 A1
20020192159 Reitberg Dec 2002 A1
20020193669 Glukhovsky Dec 2002 A1
20020193846 Pool et al. Dec 2002 A1
20020198470 Imran et al. Dec 2002 A1
20030017826 Fishman Jan 2003 A1
20030023150 Yokoi et al. Jan 2003 A1
20030028226 Thompson Feb 2003 A1
20030037063 Schwartz Feb 2003 A1
20030063522 Sagar Apr 2003 A1
20030065536 Hansen Apr 2003 A1
20030076179 Branch et al. Apr 2003 A1
20030083559 Thompson May 2003 A1
20030126593 Mault Jul 2003 A1
20030130714 Nielsen et al. Jul 2003 A1
20030135128 Suffin et al. Jul 2003 A1
20030135392 Vrijens et al. Jul 2003 A1
20030152622 Louie-Helm et al. Aug 2003 A1
20030158466 Lynn et al. Aug 2003 A1
20030158756 Abramson Aug 2003 A1
20030162556 Libes Aug 2003 A1
20030164401 Andreasson et al. Sep 2003 A1
20030167000 Mullick et al. Sep 2003 A1
20030171791 KenKnight Sep 2003 A1
20030171898 Tarassenko et al. Sep 2003 A1
20030181788 Yokoi et al. Sep 2003 A1
20030181815 Ebner et al. Sep 2003 A1
20030185286 Yuen Oct 2003 A1
20030187337 Tarassenko et al. Oct 2003 A1
20030187338 Say et al. Oct 2003 A1
20030195403 Berner et al. Oct 2003 A1
20030198619 Dong et al. Oct 2003 A1
20030213495 Fujita et al. Nov 2003 A1
20030214579 Iddan Nov 2003 A1
20030216622 Meron et al. Nov 2003 A1
20030216625 Phipps Nov 2003 A1
20030216666 Ericson et al. Nov 2003 A1
20030216729 Marchitto Nov 2003 A1
20030216793 Karlsson et al. Nov 2003 A1
20030229382 Sun et al. Dec 2003 A1
20030232895 Omidian et al. Dec 2003 A1
20040008123 Carrender et al. Jan 2004 A1
20040018476 LaDue Jan 2004 A1
20040019172 Yang et al. Jan 2004 A1
20040034295 Salganicoff Feb 2004 A1
20040049245 Gass Mar 2004 A1
20040073095 Causey et al. Apr 2004 A1
20040073454 Urquhart et al. Apr 2004 A1
20040077995 Ferek-Petric Apr 2004 A1
20040082982 Gord et al. Apr 2004 A1
20040087839 Raymond et al. May 2004 A1
20040092801 Drakulic May 2004 A1
20040106859 Say et al. Jun 2004 A1
20040111011 Uchiyama et al. Jun 2004 A1
20040115507 Potter et al. Jun 2004 A1
20040115517 Fukuda et al. Jun 2004 A1
20040121015 Chidlaw et al. Jun 2004 A1
20040122296 Hatlestad Jun 2004 A1
20040122297 Stahmann et al. Jun 2004 A1
20040138558 Dunki-Jacobs et al. Jul 2004 A1
20040147326 Stiles Jul 2004 A1
20040148140 Tarassenko et al. Jul 2004 A1
20040153007 Harris Aug 2004 A1
20040167226 Serafini Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040171914 Avni Sep 2004 A1
20040193020 Chiba Sep 2004 A1
20040193029 Glukhovsky Sep 2004 A1
20040193446 Mayer et al. Sep 2004 A1
20040199222 Sun et al. Oct 2004 A1
20040215084 Shimizu et al. Oct 2004 A1
20040218683 Batra Nov 2004 A1
20040220643 Schmidt Nov 2004 A1
20040224644 Wu Nov 2004 A1
20040225199 Evanyk Nov 2004 A1
20040253304 Gross et al. Dec 2004 A1
20040258571 Lee et al. Dec 2004 A1
20040260154 Sidelnik Dec 2004 A1
20040267240 Gross et al. Dec 2004 A1
20050017841 Doi Jan 2005 A1
20050020887 Goldberg Jan 2005 A1
20050021103 DiLorenzo Jan 2005 A1
20050021370 Riff Jan 2005 A1
20050021372 Mikkelsen Jan 2005 A1
20050024198 Ward Feb 2005 A1
20050027175 Yang Feb 2005 A1
20050027205 Tarassenko et al. Feb 2005 A1
20050038321 Fujita et al. Feb 2005 A1
20050038680 McMahon Feb 2005 A1
20050043583 Killman et al. Feb 2005 A1
20050043634 Yokoi et al. Feb 2005 A1
20050043894 Fernandez Feb 2005 A1
20050054897 Hashimoto et al. Mar 2005 A1
20050055014 Coppeta et al. Mar 2005 A1
20050062644 Leci Mar 2005 A1
20050065407 Nakamura et al. Mar 2005 A1
20050070778 Lackey Mar 2005 A1
20050090753 Goor et al. Apr 2005 A1
20050092108 Andermo May 2005 A1
20050096514 Starkebaum May 2005 A1
20050096562 Delalic et al. May 2005 A1
20050101843 Quinn May 2005 A1
20050101872 Sattler May 2005 A1
20050115561 Stahmann et al. Jun 2005 A1
20050116820 Goldreich Jun 2005 A1
20050117389 Worledge Jun 2005 A1
20050121322 Say et al. Jun 2005 A1
20050131281 Ayer et al. Jun 2005 A1
20050137480 Alt et al. Jun 2005 A1
20050143623 Kojima Jun 2005 A1
20050146594 Nakatani et al. Jul 2005 A1
20050148883 Boesen Jul 2005 A1
20050151625 Lai Jul 2005 A1
20050154277 Tang et al. Jul 2005 A1
20050154428 Bruinsma Jul 2005 A1
20050156709 Gilbert et al. Jul 2005 A1
20050159789 Brockway Jul 2005 A1
20050165323 Montgomery Jul 2005 A1
20050177069 Takizawa Aug 2005 A1
20050182389 LaPorte Aug 2005 A1
20050187789 Hatlestad et al. Aug 2005 A1
20050192489 Marshall Sep 2005 A1
20050197680 DelMain et al. Sep 2005 A1
20050228268 Cole Oct 2005 A1
20050234307 Heinonen Oct 2005 A1
20050240305 Bogash et al. Oct 2005 A1
20050245794 Dinsmoor Nov 2005 A1
20050245839 Stivoric et al. Nov 2005 A1
20050259768 Yang et al. Nov 2005 A1
20050261559 Mumford Nov 2005 A1
20050267550 Hess et al. Dec 2005 A1
20050267556 Shuros et al. Dec 2005 A1
20050267756 Schultz et al. Dec 2005 A1
20050277912 John Dec 2005 A1
20050277999 Strother et al. Dec 2005 A1
20050280539 Pettus Dec 2005 A1
20050285732 Sengupta et al. Dec 2005 A1
20050285746 Sengupta Dec 2005 A1
20050288594 Lewkowicz et al. Dec 2005 A1
20060001496 Abrosimov et al. Jan 2006 A1
20060028727 Moon et al. Feb 2006 A1
20060036134 Tarassenko et al. Feb 2006 A1
20060058602 Kwiatkowski et al. Mar 2006 A1
20060061472 Lovoi et al. Mar 2006 A1
20060065713 Kingery Mar 2006 A1
20060068006 Begleiter Mar 2006 A1
20060074283 Henderson Apr 2006 A1
20060074319 Barnes et al. Apr 2006 A1
20060078765 Yang et al. Apr 2006 A1
20060089858 Ling Apr 2006 A1
20060095091 Drew May 2006 A1
20060095093 Bettesh et al. May 2006 A1
20060100533 Han May 2006 A1
20060109058 Keating May 2006 A1
20060110962 Powell May 2006 A1
20060122474 Teller et al. Jun 2006 A1
20060122667 Chavan et al. Jun 2006 A1
20060129060 Lee et al. Jun 2006 A1
20060136266 Tarassenko et al. Jun 2006 A1
20060142648 Banet Jun 2006 A1
20060145876 Kimura Jul 2006 A1
20060148254 McLean Jul 2006 A1
20060149339 Burnes Jul 2006 A1
20060155174 Glukhovsky et al. Jul 2006 A1
20060155183 Kroecker Jul 2006 A1
20060158820 Takiguchi Jul 2006 A1
20060161225 Sormann et al. Jul 2006 A1
20060179949 Kim Aug 2006 A1
20060183992 Kawashima Aug 2006 A1
20060183993 Horn Aug 2006 A1
20060184092 Atanasoska et al. Aug 2006 A1
20060204738 Dubrow et al. Sep 2006 A1
20060204764 Hirao et al. Sep 2006 A1
20060210626 Spaeder Sep 2006 A1
20060216603 Choi Sep 2006 A1
20060218011 Walker Sep 2006 A1
20060229053 Sivard Oct 2006 A1
20060235489 Drew Oct 2006 A1
20060243288 Kim et al. Nov 2006 A1
20060247505 Siddiqui Nov 2006 A1
20060253004 Frisch et al. Nov 2006 A1
20060253005 Drinan Nov 2006 A1
20060255064 Donaldson Nov 2006 A1
20060265246 Hoag Nov 2006 A1
20060267774 Feinberg et al. Nov 2006 A1
20060270346 Ibrahim Nov 2006 A1
20060273882 Posamentier Dec 2006 A1
20060276702 McGinnis Dec 2006 A1
20060280227 Pinkney Dec 2006 A1
20060282001 Noel Dec 2006 A1
20060285607 Strodtbeck et al. Dec 2006 A1
20060287693 Kraft et al. Dec 2006 A1
20060289640 Mercure Dec 2006 A1
20060293607 Alt Dec 2006 A1
20070000776 Karube et al. Jan 2007 A1
20070002038 Suzuki Jan 2007 A1
20070006636 King et al. Jan 2007 A1
20070008113 Spoonhower et al. Jan 2007 A1
20070016089 Fischell et al. Jan 2007 A1
20070027386 Such Feb 2007 A1
20070027388 Chou Feb 2007 A1
20070038054 Zhou Feb 2007 A1
20070049339 Barak et al. Mar 2007 A1
20070055098 Shimizu et al. Mar 2007 A1
20070060797 Ball Mar 2007 A1
20070060800 Drinan et al. Mar 2007 A1
20070066929 Ferren et al. Mar 2007 A1
20070072156 Kaufman et al. Mar 2007 A1
20070073353 Rooney et al. Mar 2007 A1
20070088194 Tahar Apr 2007 A1
20070096765 Kagan May 2007 A1
20070106346 Bergelson May 2007 A1
20070123772 Euliano May 2007 A1
20070129622 Bourget Jun 2007 A1
20070130287 Kumar Jun 2007 A1
20070135691 Zingelewicz et al. Jun 2007 A1
20070135803 Belson Jun 2007 A1
20070142721 Berner et al. Jun 2007 A1
20070156016 Betesh Jul 2007 A1
20070160789 Merical Jul 2007 A1
20070162089 Mosesov Jul 2007 A1
20070162090 Penner Jul 2007 A1
20070167495 Brown et al. Jul 2007 A1
20070167848 Kuo et al. Jul 2007 A1
20070172424 Roser Jul 2007 A1
20070173701 Al-Ali Jul 2007 A1
20070177770 Derchak Aug 2007 A1
20070179347 Tarassenko et al. Aug 2007 A1
20070179371 Peyser et al. Aug 2007 A1
20070180047 Dong et al. Aug 2007 A1
20070185393 Zhou Aug 2007 A1
20070191002 Ge Aug 2007 A1
20070196456 Stevens Aug 2007 A1
20070207793 Myer Sep 2007 A1
20070207858 Breving Sep 2007 A1
20070208233 Kovacs Sep 2007 A1
20070213659 Trovato et al. Sep 2007 A1
20070237719 Jones Oct 2007 A1
20070244370 Kuo et al. Oct 2007 A1
20070244810 Rudolph Oct 2007 A1
20070249946 Kumar et al. Oct 2007 A1
20070255198 Leong et al. Nov 2007 A1
20070255330 Lee Nov 2007 A1
20070270672 Hayter Nov 2007 A1
20070279217 Venkatraman Dec 2007 A1
20070282174 Sabatino Dec 2007 A1
20070282177 Pilz Dec 2007 A1
20070291715 Laroia et al. Dec 2007 A1
20070299480 Hill Dec 2007 A1
20080004503 Nisani et al. Jan 2008 A1
20080014866 Lipowshi Jan 2008 A1
20080015421 Penner Jan 2008 A1
20080015494 Santini et al. Jan 2008 A1
20080015893 Miller et al. Jan 2008 A1
20080020037 Robertson et al. Jan 2008 A1
20080021519 DeGeest Jan 2008 A1
20080021521 Shah Jan 2008 A1
20080027679 Shklarski Jan 2008 A1
20080033273 Zhou Feb 2008 A1
20080033301 DellaVecchia et al. Feb 2008 A1
20080038588 Lee Feb 2008 A1
20080039700 Drinan et al. Feb 2008 A1
20080045843 Tsuji et al. Feb 2008 A1
20080046038 Hill Feb 2008 A1
20080051647 Wu et al. Feb 2008 A1
20080051667 Goldreich Feb 2008 A1
20080058614 Banet Mar 2008 A1
20080062856 Feher Mar 2008 A1
20080065168 Bitton et al. Mar 2008 A1
20080074307 Boric-Lubecke Mar 2008 A1
20080077015 Boric-Lubecke Mar 2008 A1
20080077028 Schaldach et al. Mar 2008 A1
20080077188 Denker et al. Mar 2008 A1
20080077430 Singer et al. Mar 2008 A1
20080091089 Guillory et al. Apr 2008 A1
20080091114 Min Apr 2008 A1
20080097549 Colbaugh Apr 2008 A1
20080097917 Dicks Apr 2008 A1
20080099366 Niemiec et al. May 2008 A1
20080103440 Ferren et al. May 2008 A1
20080112885 Okunev et al. May 2008 A1
20080114224 Bandy et al. May 2008 A1
20080119705 Patel May 2008 A1
20080119716 Boric-Lubecke May 2008 A1
20080121825 Trovato et al. May 2008 A1
20080137566 Marholev Jun 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080140403 Hughes et al. Jun 2008 A1
20080146871 Arneson et al. Jun 2008 A1
20080146889 Young Jun 2008 A1
20080146892 LeBoeuf Jun 2008 A1
20080154104 Lamego Jun 2008 A1
20080166992 Ricordi Jul 2008 A1
20080175898 Jones et al. Jul 2008 A1
20080183245 Van Oort Jul 2008 A1
20080188763 John et al. Aug 2008 A1
20080188837 Belsky et al. Aug 2008 A1
20080194912 Trovato et al. Aug 2008 A1
20080208009 Shklarski Aug 2008 A1
20080214901 Gehman Sep 2008 A1
20080214903 Orbach Sep 2008 A1
20080214985 Yanaki Sep 2008 A1
20080223936 Mickle et al. Sep 2008 A1
20080243020 Chou Oct 2008 A1
20080249360 Li Oct 2008 A1
20080262320 Schaefer et al. Oct 2008 A1
20080262336 Ryu Oct 2008 A1
20080269664 Trovato et al. Oct 2008 A1
20080275312 Mosesov Nov 2008 A1
20080281636 Jung et al. Nov 2008 A1
20080284599 Zdeblick et al. Nov 2008 A1
20080288026 Cross et al. Nov 2008 A1
20080288027 Kroll Nov 2008 A1
20080294020 Sapounas Nov 2008 A1
20080299197 Toneguzzo et al. Dec 2008 A1
20080300572 Rankers Dec 2008 A1
20080303638 Nguyen Dec 2008 A1
20080303665 Naik et al. Dec 2008 A1
20080306357 Korman Dec 2008 A1
20080306359 Zdeblick et al. Dec 2008 A1
20080306360 Robertson et al. Dec 2008 A1
20080306362 Davis Dec 2008 A1
20080311852 Hansen Dec 2008 A1
20080312522 Rowlandson Dec 2008 A1
20080316020 Robertson Dec 2008 A1
20090006133 Weinert et al. Jan 2009 A1
20090009330 Sakama et al. Jan 2009 A1
20090009332 Nunez et al. Jan 2009 A1
20090024045 Prakash Jan 2009 A1
20090024112 Edwards et al. Jan 2009 A1
20090030297 Miller Jan 2009 A1
20090034209 Joo Feb 2009 A1
20090043171 Rule Feb 2009 A1
20090048498 Riskey Feb 2009 A1
20090062634 Say et al. Mar 2009 A1
20090062670 Sterling Mar 2009 A1
20090062730 Woo Mar 2009 A1
20090069642 Gao Mar 2009 A1
20090069655 Say et al. Mar 2009 A1
20090069656 Say et al. Mar 2009 A1
20090069657 Say et al. Mar 2009 A1
20090069658 Say et al. Mar 2009 A1
20090076340 Libbus et al. Mar 2009 A1
20090076343 James Mar 2009 A1
20090076350 Bly et al. Mar 2009 A1
20090076397 Libbus et al. Mar 2009 A1
20090082645 Hafezi et al. Mar 2009 A1
20090087483 Sison Apr 2009 A1
20090088618 Ameson Apr 2009 A1
20090099435 Say et al. Apr 2009 A1
20090110148 Zhang Apr 2009 A1
20090112626 Talbot Apr 2009 A1
20090124871 Arshak May 2009 A1
20090131774 Sweitzer May 2009 A1
20090134181 Wachman et al. May 2009 A1
20090135886 Robertson et al. May 2009 A1
20090142853 Warrington et al. Jun 2009 A1
20090149708 Hyde et al. Jun 2009 A1
20090149839 Hyde et al. Jun 2009 A1
20090157113 Marcotte Jun 2009 A1
20090157358 Kim Jun 2009 A1
20090161602 Matsumoto Jun 2009 A1
20090163789 Say et al. Jun 2009 A1
20090171180 Pering Jul 2009 A1
20090173628 Say et al. Jul 2009 A1
20090177055 Say et al. Jul 2009 A1
20090177056 Say et al. Jul 2009 A1
20090177057 Say et al. Jul 2009 A1
20090177058 Say et al. Jul 2009 A1
20090177059 Say et al. Jul 2009 A1
20090177060 Say et al. Jul 2009 A1
20090177061 Say et al. Jul 2009 A1
20090177062 Say et al. Jul 2009 A1
20090177063 Say et al. Jul 2009 A1
20090177064 Say et al. Jul 2009 A1
20090177065 Say et al. Jul 2009 A1
20090177066 Say et al. Jul 2009 A1
20090182206 Najafi Jul 2009 A1
20090182207 Riskey et al. Jul 2009 A1
20090182212 Say et al. Jul 2009 A1
20090182213 Say et al. Jul 2009 A1
20090182214 Say et al. Jul 2009 A1
20090182215 Say et al. Jul 2009 A1
20090182388 Von Arx Jul 2009 A1
20090187088 Say et al. Jul 2009 A1
20090187089 Say et al. Jul 2009 A1
20090187090 Say et al. Jul 2009 A1
20090187091 Say et al. Jul 2009 A1
20090187092 Say et al. Jul 2009 A1
20090187093 Say et al. Jul 2009 A1
20090187094 Say et al. Jul 2009 A1
20090187095 Say et al. Jul 2009 A1
20090187381 King et al. Jul 2009 A1
20090192351 Nishino Jul 2009 A1
20090192368 Say et al. Jul 2009 A1
20090192369 Say et al. Jul 2009 A1
20090192370 Say et al. Jul 2009 A1
20090192371 Say et al. Jul 2009 A1
20090192372 Say et al. Jul 2009 A1
20090192373 Say et al. Jul 2009 A1
20090192374 Say et al. Jul 2009 A1
20090192375 Say et al. Jul 2009 A1
20090192376 Say et al. Jul 2009 A1
20090192377 Say et al. Jul 2009 A1
20090192378 Say et al. Jul 2009 A1
20090192379 Say et al. Jul 2009 A1
20090198115 Say et al. Aug 2009 A1
20090198116 Say et al. Aug 2009 A1
20090198175 Say et al. Aug 2009 A1
20090203964 Shimizu et al. Aug 2009 A1
20090203971 Sciarappa Aug 2009 A1
20090203972 Heneghan Aug 2009 A1
20090203978 Say et al. Aug 2009 A1
20090204265 Hackett Aug 2009 A1
20090210164 Say et al. Aug 2009 A1
20090216101 Say et al. Aug 2009 A1
20090216102 Say et al. Aug 2009 A1
20090227204 Robertson et al. Sep 2009 A1
20090227876 Tran Sep 2009 A1
20090227940 Say et al. Sep 2009 A1
20090227941 Say et al. Sep 2009 A1
20090227988 Wood et al. Sep 2009 A1
20090228214 Say et al. Sep 2009 A1
20090231125 Baldus Sep 2009 A1
20090234200 Husheer Sep 2009 A1
20090243833 Huang Oct 2009 A1
20090247836 Cole et al. Oct 2009 A1
20090253960 Takenaka et al. Oct 2009 A1
20090256702 Robertson Oct 2009 A1
20090264714 Chou Oct 2009 A1
20090264964 Abrahamson Oct 2009 A1
20090265186 Tarassenko et al. Oct 2009 A1
20090273467 Elixmann Nov 2009 A1
20090277815 Kohl et al. Nov 2009 A1
20090281539 Selig Nov 2009 A1
20090287109 Ferren et al. Nov 2009 A1
20090292194 Libbus et al. Nov 2009 A1
20090295548 Ronkka Dec 2009 A1
20090296677 Mahany Dec 2009 A1
20090301925 Alloro et al. Dec 2009 A1
20090303920 Mahany Dec 2009 A1
20090306633 Trovato et al. Dec 2009 A1
20090312619 Say et al. Dec 2009 A1
20090318303 Delamarche et al. Dec 2009 A1
20090318761 Rabinovitz Dec 2009 A1
20090318779 Tran Dec 2009 A1
20090318783 Rohde Dec 2009 A1
20090318793 Datta Dec 2009 A1
20100001841 Cardullo Jan 2010 A1
20100006585 Flowers et al. Jan 2010 A1
20100010330 Rankers Jan 2010 A1
20100015584 Singer et al. Jan 2010 A1
20100033324 Shimizu et al. Feb 2010 A1
20100036269 Ferren et al. Feb 2010 A1
20100049004 Edman et al. Feb 2010 A1
20100049006 Magar Feb 2010 A1
20100049012 Dijksman et al. Feb 2010 A1
20100049069 Tarassenko et al. Feb 2010 A1
20100056878 Partin Mar 2010 A1
20100056891 Say et al. Mar 2010 A1
20100056939 Tarassenko et al. Mar 2010 A1
20100057041 Hayter Mar 2010 A1
20100062709 Kato Mar 2010 A1
20100063438 Bengtsson Mar 2010 A1
20100063841 D'Ambrosia et al. Mar 2010 A1
20100069002 Rong Mar 2010 A1
20100069717 Hafezi et al. Mar 2010 A1
20100081894 Zdeblick et al. Apr 2010 A1
20100082367 Hains et al. Apr 2010 A1
20100099967 Say et al. Apr 2010 A1
20100099968 Say et al. Apr 2010 A1
20100099969 Say et al. Apr 2010 A1
20100100077 Rush Apr 2010 A1
20100100078 Say et al. Apr 2010 A1
20100100237 Ratnakar Apr 2010 A1
20100106001 Say et al. Apr 2010 A1
20100118853 Godfrey May 2010 A1
20100131434 Magent et al. May 2010 A1
20100139672 Kroll et al. Jun 2010 A1
20100160742 Seidl et al. Jun 2010 A1
20100168659 Say et al. Jul 2010 A1
20100179398 Say et al. Jul 2010 A1
20100183199 Smith Jul 2010 A1
20100185055 Robertson Jul 2010 A1
20100191073 Tarassenko et al. Jul 2010 A1
20100203394 Bae et al. Aug 2010 A1
20100210299 Gorbachov Aug 2010 A1
20100217100 LeBoeuf et al. Aug 2010 A1
20100222652 Cho Sep 2010 A1
20100228113 Solosko Sep 2010 A1
20100233026 Ismagliov et al. Sep 2010 A1
20100234706 Gilland Sep 2010 A1
20100234715 Shin Sep 2010 A1
20100234914 Shen Sep 2010 A1
20100245091 Singh Sep 2010 A1
20100249541 Geva et al. Sep 2010 A1
20100249881 Corndorf Sep 2010 A1
20100256461 Mohamedali Oct 2010 A1
20100259543 Tarassenko et al. Oct 2010 A1
20100268048 Say et al. Oct 2010 A1
20100268049 Say et al. Oct 2010 A1
20100268050 Say et al. Oct 2010 A1
20100268288 Hunter et al. Oct 2010 A1
20100274111 Say et al. Oct 2010 A1
20100280345 Say et al. Nov 2010 A1
20100280346 Say et al. Nov 2010 A1
20100295694 Kauffman et al. Nov 2010 A1
20100298668 Hafezi et al. Nov 2010 A1
20100298730 Tarassenko et al. Nov 2010 A1
20100299155 Findlay et al. Nov 2010 A1
20100312188 Robertson et al. Dec 2010 A1
20100312577 Goodnow et al. Dec 2010 A1
20100312580 Tarassenko et al. Dec 2010 A1
20100332443 Gartenberg Dec 2010 A1
20110004079 Al Ali et al. Jan 2011 A1
20110009715 O'Reilly et al. Jan 2011 A1
20110021983 Jurson Jan 2011 A1
20110029622 Walker et al. Feb 2011 A1
20110040203 Savage et al. Feb 2011 A1
20110050431 Hood et al. Mar 2011 A1
20110054265 Hafezi et al. Mar 2011 A1
20110065983 Hafezi et al. Mar 2011 A1
20110077660 Janik et al. Mar 2011 A1
20110081860 Brown et al. Apr 2011 A1
20110105864 Robertson et al. May 2011 A1
20110112686 Nolan et al. May 2011 A1
20110124983 Kroll et al. May 2011 A1
20110144470 Mazar et al. Jun 2011 A1
20110160549 Saroka et al. Jun 2011 A1
20110212782 Thompson et al. Sep 2011 A1
20110224912 Bhavaraju et al. Sep 2011 A1
20110230732 Edman et al. Sep 2011 A1
20110237924 McGusty et al. Sep 2011 A1
20110270112 Manera et al. Nov 2011 A1
20110270135 Dooley et al. Nov 2011 A1
20110279963 Kumar et al. Nov 2011 A1
20120011699 Hafezi et al. Jan 2012 A1
20120024889 Robertson et al. Feb 2012 A1
20120029309 Paquet et al. Feb 2012 A1
20120032816 Cho et al. Feb 2012 A1
20120062371 Radivojevic et al. Mar 2012 A1
20120071743 Todorov et al. Mar 2012 A1
20120083715 Yuen et al. Apr 2012 A1
20120089000 Bishay et al. Apr 2012 A1
20120101396 Solosko et al. Apr 2012 A1
20120116184 Shieh May 2012 A1
20120179004 Roesicke et al. Jul 2012 A1
20120197144 Christ et al. Aug 2012 A1
20120214140 Brynelsen et al. Aug 2012 A1
20120265544 Hwang et al. Oct 2012 A1
20120299723 Hafezi et al. Nov 2012 A1
20120310070 Kumar et al. Dec 2012 A1
20120316413 Liu et al. Dec 2012 A1
20130002423 Robertson et al. Jan 2013 A1
20130030259 Thomsen et al. Jan 2013 A1
20130057385 Murakami et al. Mar 2013 A1
20130060115 Gehman et al. Mar 2013 A1
20130171596 French Jul 2013 A1
20130185228 Dresner Jul 2013 A1
20130196012 Dill Aug 2013 A1
20130275296 Tietzen et al. Oct 2013 A1
20130328416 Whitworth et al. Dec 2013 A1
20130338452 Robertson et al. Dec 2013 A1
20140004492 O'Reilly et al. Jan 2014 A1
20140039445 Austin et al. Feb 2014 A1
20140051965 Zdeblick et al. Feb 2014 A1
20140203950 Zdeblick et al. Jul 2014 A1
20140280125 Bhardwaj et al. Sep 2014 A1
20140308930 Tran Oct 2014 A1
20140315170 Ionescu et al. Oct 2014 A1
20140334575 Arne et al. Nov 2014 A1
20140349256 Connor Nov 2014 A1
20140374276 Guthrie et al. Dec 2014 A1
20150048929 Robertson et al. Feb 2015 A1
20150051465 Robertson et al. Feb 2015 A1
20150080677 Thompson et al. Mar 2015 A1
20150080678 Frank et al. Mar 2015 A1
20150080679 Frank et al. Mar 2015 A1
20150080680 Zdeblick et al. Mar 2015 A1
20150080681 Hafezi et al. Mar 2015 A1
20150127737 Thompson et al. May 2015 A1
20150127738 Thompson et al. May 2015 A1
20150149375 Thompson et al. May 2015 A1
20150165313 Thompson et al. Jun 2015 A1
20150171924 Zdeblick Jun 2015 A1
20150182463 Hafezi et al. Jul 2015 A1
20150193593 Zdeblick et al. Jul 2015 A1
20150230728 Hafezi et al. Aug 2015 A1
20160106339 Behzadi et al. Apr 2016 A1
20160155316 Hafezi et al. Jun 2016 A1
20170000180 Arne et al. Jan 2017 A1
20170215761 Zdeblick Aug 2017 A1
20170270779 Zdeblick et al. Sep 2017 A1
20170290513 O'Reilly et al. Oct 2017 A1
20170303818 Behzadi et al. Oct 2017 A1
20180026680 Shirvani et al. Jan 2018 A1
20180184698 Arne et al. Jul 2018 A1
20180279910 Jensen et al. Oct 2018 A1
Foreign Referenced Citations (244)
Number Date Country
2953847 Nov 2006 CA
1588649 Mar 2005 CN
2748032 Dec 2005 CN
1991868 Jul 2007 CN
101005470 Jul 2007 CN
201076456 Jun 2008 CN
101524267 Sep 2009 CN
10313005 Oct 2004 DE
0344939 Dec 1989 EP
0526166 Feb 1993 EP
1199670 Apr 2002 EP
1246356 Oct 2002 EP
1342447 Sep 2003 EP
1534054 May 2005 EP
1702553 Sep 2006 EP
1098591 Jan 2007 EP
2143369 Jan 2010 EP
775071 May 1957 GB
2432862 Jun 2007 GB
172917 Jun 2010 IL
61017949 Jan 1986 JP
S63280393 Nov 1988 JP
H01285247 Nov 1989 JP
05-228128 Sep 1993 JP
H0646539 Feb 1994 JP
H0884779 Apr 1996 JP
09-330159 Dec 1997 JP
10-14898 Jan 1998 JP
H11195415 Jul 1999 JP
2000-506410 May 2000 JP
2001078974 Mar 2001 JP
2002-224053 Aug 2002 JP
2002263185 Sep 2002 JP
2002282218 Oct 2002 JP
2002282219 Oct 2002 JP
2002291684 Oct 2002 JP
2003210395 Jul 2003 JP
2003325440 Nov 2003 JP
2004-7187 Jan 2004 JP
2004507188 Mar 2004 JP
2004-134384 Apr 2004 JP
2004274452 Sep 2004 JP
2004-313242 Nov 2004 JP
2004318534 Nov 2004 JP
2004364016 Dec 2004 JP
2005031840 Feb 2005 JP
2005-073886 Mar 2005 JP
2005-087552 Apr 2005 JP
2005-304880 Apr 2005 JP
2005124708 May 2005 JP
2005148021 Jun 2005 JP
2005152037 Jun 2005 JP
2005287691 Oct 2005 JP
2005-532841 Nov 2005 JP
2005-532849 Nov 2005 JP
2005343515 Dec 2005 JP
2006006377 Jan 2006 JP
2006509574 Mar 2006 JP
2006-177699 Jul 2006 JP
2006-187611 Jul 2006 JP
2006278091 Oct 2006 JP
2006346000 Dec 2006 JP
3876573 Jan 2007 JP
2007151809 Jun 2007 JP
2007159631 Jun 2007 JP
2007200739 Aug 2007 JP
2007-313340 Dec 2007 JP
2007-330677 Dec 2007 JP
2008011865 Jan 2008 JP
2008501415 Jan 2008 JP
2008176434 Jul 2008 JP
2008191955 Aug 2008 JP
2008289724 Dec 2008 JP
2009034345 Feb 2009 JP
2009-061236 Mar 2009 JP
2009050541 Mar 2009 JP
2009065726 Mar 2009 JP
2011015817 Jan 2011 JP
2011519583 Jul 2011 JP
20020015907 Mar 2002 KR
20020061744 Jul 2002 KR
200609977523 Jul 2006 KR
927471 Nov 2009 KR
20110137001 Dec 2011 KR
10-2012-09995 Sep 2012 KR
200301864 Jul 2003 TW
553735 Sep 2003 TW
200724094 Jul 2007 TW
200812556 Mar 2008 TW
201120673 Jun 2011 TW
WO1988002237 Apr 1988 WO
WO1992021307 Dec 1992 WO
WO1993008734 May 1993 WO
WO1993019667 Oct 1993 WO
WO1994001165 Jan 1994 WO
WO9516393 Jun 1995 WO
WO1997014112 Apr 1997 WO
WO1997039963 Oct 1997 WO
WO1998043537 Oct 1998 WO
WO1999037290 Jul 1999 WO
WO1999059465 Nov 1999 WO
WO2000033246 Jun 2000 WO
WO2001000085 Jan 2001 WO
WO2001047466 Jul 2001 WO
WO2001049364 Jul 2001 WO
WO2001074011 Oct 2001 WO
WO2001080731 Nov 2001 WO
WO0235997 May 2002 WO
WO2002045489 Jun 2002 WO
WO2002058330 Jul 2002 WO
WO2002062276 Aug 2002 WO
WO2002087681 Nov 2002 WO
WO2002095351 Nov 2002 WO
WO2003005877 Jan 2003 WO
WO2003050643 Jun 2003 WO
WO2003068061 Aug 2003 WO
WO2004014225 Feb 2004 WO
WO2004019172 Mar 2004 WO
WO2004039256 May 2004 WO
WO2004059551 Jul 2004 WO
WO2004066833 Aug 2004 WO
WO2004066834 Aug 2004 WO
WO2004066903 Aug 2004 WO
WO2004068748 Aug 2004 WO
WO2004068881 Aug 2004 WO
WO2004075751 Sep 2004 WO
WO2004109316 Dec 2004 WO
WO2004110555 Dec 2004 WO
WO2005011237 Feb 2005 WO
WO2005020023 Mar 2005 WO
WO2005024687 Mar 2005 WO
WO2005041767 May 2005 WO
WO2005047837 May 2005 WO
WO2005051166 Jun 2005 WO
WO2005053517 Jun 2005 WO
WO2005069887 Aug 2005 WO
WO2005082436 Sep 2005 WO
WO2005083621 Sep 2005 WO
WO2005110238 Nov 2005 WO
WO2005117697 Dec 2005 WO
WO2006009404 Jan 2006 WO
WO2006016370 Feb 2006 WO
WO2006021932 Mar 2006 WO
WO2006027586 Mar 2006 WO
WO2006028347 Mar 2006 WO
WO2006035351 Apr 2006 WO
WO2006037802 Apr 2006 WO
WO2006046648 May 2006 WO
WO2006055892 May 2006 WO
WO2006055956 May 2006 WO
WO2006059338 Jun 2006 WO
WO2006075016 Jul 2006 WO
WO2006100620 Sep 2006 WO
WO2006109072 Oct 2006 WO
WO2006116718 Nov 2006 WO
WO2006119345 Nov 2006 WO
WO2006123346 Nov 2006 WO
WO2006127355 Nov 2006 WO
WO2007001724 Jan 2007 WO
WO2007001742 Jan 2007 WO
WO2007013952 Feb 2007 WO
WO2007014084 Feb 2007 WO
WO2007014527 Feb 2007 WO
WO2007021496 Feb 2007 WO
WO2007027660 Mar 2007 WO
WO2007028035 Mar 2007 WO
WO2007036687 Apr 2007 WO
WO2007036741 Apr 2007 WO
WO2007036746 Apr 2007 WO
WO2007040878 Apr 2007 WO
WO2007067054 Jun 2007 WO
WO2007071180 Jun 2007 WO
WO2007096810 Aug 2007 WO
WO2007101141 Sep 2007 WO
WO2007115087 Oct 2007 WO
WO2007120946 Oct 2007 WO
WO2007123923 Nov 2007 WO
WO2007127316 Nov 2007 WO
WO2007127879 Nov 2007 WO
WO2007127945 Nov 2007 WO
WO2007128165 Nov 2007 WO
WO2007130491 Nov 2007 WO
WO2007133526 Nov 2007 WO
WO2007143535 Dec 2007 WO
WO2007149546 Dec 2007 WO
WO2006104843 Jan 2008 WO
WO2008008281 Jan 2008 WO
WO2008012700 Jan 2008 WO
WO2008030482 Mar 2008 WO
WO2008039030 Apr 2008 WO
WO2008052136 May 2008 WO
WO2008061138 May 2008 WO
WO2008063626 May 2008 WO
WO2008066617 Jun 2008 WO
WO2008076464 Jun 2008 WO
WO2008085131 Jul 2008 WO
WO2008089232 Jul 2008 WO
WO2008091683 Jul 2008 WO
WO2008095183 Aug 2008 WO
WO2008097652 Aug 2008 WO
WO2008101107 Aug 2008 WO
WO2008112577 Sep 2008 WO
WO2008112578 Sep 2008 WO
WO2008120156 Oct 2008 WO
WO2008133394 Nov 2008 WO
WO2008134185 Nov 2008 WO
WO2008150633 Dec 2008 WO
WO2009001108 Dec 2008 WO
WO2009005759 Jan 2009 WO
WO2009006615 Jan 2009 WO
WO2009022343 Feb 2009 WO
WO2009029453 Mar 2009 WO
WO2009032381 Mar 2009 WO
WO2009036334 Mar 2009 WO
WO2009051829 Apr 2009 WO
WO2009051830 Apr 2009 WO
WO2009063377 May 2009 WO
WO2009081348 Jul 2009 WO
WO2009111664 Sep 2009 WO
WO2009146082 Dec 2009 WO
WO2010000085 Jan 2010 WO
WO2010009100 Jan 2010 WO
WO2010011833 Jan 2010 WO
WO2010019778 Feb 2010 WO
WO2010057049 May 2010 WO
WO2010075115 Jul 2010 WO
WO2010080765 Jul 2010 WO
WO2010080843 Jul 2010 WO
WO2010107563 Sep 2010 WO
WO2010107980 Sep 2010 WO
WO2010115194 Oct 2010 WO
WO2010132331 Nov 2010 WO
WO2010135516 Nov 2010 WO
WO2011024560 Mar 2011 WO
WO2011068963 Jun 2011 WO
WO2011133799 Oct 2011 WO
WO2011159336 Dec 2011 WO
WO2011159337 Dec 2011 WO
WO2011159338 Dec 2011 WO
WO2011159339 Dec 2011 WO
WO2012104657 Aug 2012 WO
WO2012158190 Nov 2012 WO
WO2013012869 Jan 2013 WO
WO2015112603 Jul 2015 WO
Non-Patent Literature Citations (110)
Entry
Hotz “The Really Smart Phone” The Wall Street Journal, What They Know (2011); 6 pp.; http://online.wsj.com/article/SB10001424052748704547604576263261679848814.html?mod=djemTECH_t.
Evanczuk, S., “PIC MCU software library uses human body for secure communications link” EDN Network; edn.com; Feb. 26, 2013 Retrieved from Internet Jun. 19, 2013 at http://www.edn.com/electronics-products/other/4407842/PIC-MCU-software-library-uses-human-body-for-secure-communications-link; 5 pp.
AADE, “AADE 37th Annual Meeting San Antonio Aug. 4-7, 2010” American Association of Diabetes Educators Aug. 2010; http://www.diabeteseducator.org/annualmeeting/2010/index.html; 2 pp.
Arshak et al., A Review and Adaptation of Methods of Object Tracking to Telemetry Capsules IC-Med; Jan. 2007 vol. 1, No. 1, Issue 1, 12pp.
“ASGE Technology Status Evaluation Report: wireless capsule endoscopy” American Soc. For Gastrointestinal Endoscopy; Apr. 2006 vol. 63, No. 4; 7 pp.
Aydin et al., “Design and implementation considerations for an advanced wireless interface in miniaturized integrated sensor Microsystems” Sch. of Eng. & Electron., Edinburgh Univ., UK; Sep. 2003; Abstract Only.
Barrie, Heidelberg pH capsule gastric analysis. Texbook of Natural Medicine, (1992), Pizzorno, Murray & Barrie.
Baskiyar, S. “A Real-time Fault Tolerant Intra-body Network” Dept. of Comp. Sci & Soft Eng; Auburn University; Proceedings of the 27th Annual IEEE Conference; 0742-1303/02 (2002) IEEE; 6 pp.
Bohidar et al., “Dielectric Behavior of Gelatin Solutions and Gels” Colloid Polym Sci (1998) 276:81-86.
Brock, “Smart Medicine: The Application of Auto-ID Technology to Healthcare” Auto-ID Labs (2002) http://www.autoidlabs.org/uploads/media/MIT-AUTOID-WH-010.pdf.
Carlson et al., “Evaluation of a non-invasive respiratory monitoring system for sleeping subjects” Physiological Measurement (1999) 20(1): 53.
Coury, L. “Conductance Measurement Part 1: Theory”; Current Separations, 18:3 (1999) p. 91-96.
Delvaux et al., “Capsule endoscopy: Technique and indications” Clinical Gastoenterology; Oct. 2008 vol. 22, Issue 5, 1pp. (Abstract Only).
Dhar et al., “Electroless nickel plated contacts on porous silicon” Appl. Phys. Lett. 68 (10) pp. 1392-1393 (1996).
Eldek A., “Design of double dipole antenna with enhanced usable bandwidth for wideband phased array applications” Progress in Electromagnetics Research PIER 59, 1-15 (2006).
Fawaz et al., “Enhanced Telemetry System using CP-QPSK Band-Pass Modulation Technique Suitable for Smart Pill Medical Application” IFIP IEEE Dubai Conference Apr. 2008; http://www.asic.fh-offenburg.de/downloads/ePille/IFIP_IEEE_Dubai_Conference.pdf.
Ferguson et al., “Dielectric Constant Studies III Aqueous Gelatin Solutions” J. Chem. Phys. 2, 94 (1934) p. 94-98.
Furse C. M., “Dipole Antennas” J. Webster (ed). Wiley Encyclopedia of Electrical and Electronics Engineering (1999) p. 575-581.
Gaglani S. “Put Your Phone, or Skin, on Vibrate” MedGadget; Mar. 2012 http://medgadget.com/2012/03/put-your-phone-or-skin-on-vibrate.html 8pp.
Gilson, D.R. “Molecular dynamics simulation of dipole interactions”, Department of Physics, Hull University, Dec. 2002, p. 1-43.
Given Imaging, “Agile Patency Brochure” (2006) http://www.inclino.no/documents/AgilePatencyBrochure_Global_GMB-0118-01.pdf; 4pp.
Gonzalez-Guillaumin et al., “Ingestible capsule for impedance and pH monitoring in the esophagus” IEEE Trans Biomed Eng; Dec. 2007 54(12) 1pp. (Abstract Only).
Greene, “Edible RFID microchip monitor can tell if you take your medicine” Bloomberg Businessweek; Mar. 2010 2 pp.; http://www.businessweek.com/idg/2010-03-31/edible-rfid-microchip-monitor-can-tell-if-you-take-your-medicine.html.
Halthion Medical Technologies “Providing Ambulatory Medical Devices Which Monitor, Measure and Record” webpage. Online website: http://www.halthion.com/; downloaded May 30, 2012.
Heydari et al., “Analysis of the PLL jitter due to power/ground and substrate noise”; IEEE Transactions on Circuits and Systems (2004) 51(12): 2404-16.
Hoeksma, J. “New ‘smart pill’ to track adherence” E-Health-Insider May 2010 http://www.e-health-insider.com/news/5910/new_‘smartpill’_monitors_medicines.
Hoover et al., “Rx for health: Engineers design pill that signals it has been swallowed” University of Florida News; Mar. 2010 2pp.; http://news.ufl.edu/2010/03/31/antenna-pill-2/.
ISFET—Ion Sensitive Field-Effect Transistor; Microsens S.A. pdf document. First in Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 4pp.
Intromedic, MicroCam Innovative Capsule Endoscope Pamphlet. (2006) 8 pp (http://www.intromedic.com/en/product/productinfo.asp).
Jimbo et al., “Gastric-fluid-utilized micro battery for micro medical devices” The Sixth International Workshop on Micro and Nanotechnology for Power Geneartion and Energy Conservation Applications, (2006) pp. 97-100.
Jung, S. “Dissolvable ‘Transient Electronics’ Will be Good for Your Body and the Environment” MedGadget; Oct. 1, 2012; Onlne website: http://medgadget.com/2012/10/dissolvable-transient-electronics-will-be-good-for-your-body-and-the-environment.html; downloaded Oct. 24, 2012; 4 pp.
Juvenile Diabetes Research Foundation International (JDRF), “Artificial Pancreas Project” Jun. 2010; http://www.artificialpancreasproject.com/; 3 pp.
Kamada K., “Electrophoretic deposition assisted by soluble anode” Materials Letters 57 (2003) 2348-2351.
Li, P-Y, et al. “An electrochemical intraocular drug delivery device”, Sensors and Actuators A 143; p. 41-48.; Jul. 2007.
Lifescan, “OneTouch UltraLink™” http://www.lifescan.com/products/meters/ultralink; Jul. 2010 2 pp.
Lin et al., “Do Physiological Data Relate to Traditional Usability Indexes?” Proceedings of OZCHI 2005, Canberra, Australia (2005) 10 pp.
Mackay et al., “Radio Telemetering from within the Body Inside Information is Revealed by Tiny Transmitters that can be Swallowed or Implanted in Man or Animal” Science (1991) 1196-1202; 134; American Association for the Advancement of Science, Washington D.C.
Mackay et al., “Endoradiosonde” Nature, (1957) 1239-1240, 179 Nature Publishing Group.
Mandryk et al., “A physiological approach for continuously modeling user emotion in interactive play environments” Proceedings of Measuring Behavior (2008) (Maastrichtm The Netherlandsm Aug. 26-29) 2 pp.
Mandryk et al., “Objectively Evaluating Entertainment Technology” Simon Fraser University; CHI (2004) ACM 1-58113-703-6/04/0004; 2 pp.
Mckenzie et al., “Validation of a new telemetric core temperature monitor” J. Therm. Biol. (2004) 29(7-8):605-11.
Medtronic, “CareLink Therapy Management Software for Diabetes” Jul. 2010; https://carelink.minimed.com/patient/entry.jsp?bhcp=1; 1 pp.
Medtronic, “Carelink™ USB” (2008) http://www.medtronicdiabetes.com/pdf/carelink_usb_factsheet.pdf 2pp.
Medtronic “The New MiniMed Paradigm® Real-Time Revel™ System” Aug. 2010 http://www.medtronicdiabetes.com/products/index.html; 2 pp.
Medtronic, “Mini Med Paradigm® Revel™ Insulin Pump” Jul. 2010 http://www.medtronicdiabetes.com/products/insulinpumps/index.html; 2 pp.
Medtronic, Mini Med Paradigm™ Veo™ System: Factsheet (2010). http://www.medtronic-diabetes.com.au/downloads/Paradigm%20Veo%20Factsheet.pdf ; 4 pp.
Melanson, “Walkers swallow RFID pills for science” Engadget; Jul. 2008; http://www.engadget.com/2008/07/29/walkers-swallow-rfid-pills-for-science/.
Minimitter Co. Inc. “Actiheart” Traditional 510(k) Summary. Sep. 27, 2005.
Minimitter Co. Inc. Noninvasive technology to help your studies succeed. MiniMitter.com Mar. 31, 2009.
Mini Mitter Co, Inc. 510(k) Premarket Notification Mini-Logger for Diagnostic Spirometer. 9-21 (1999).
Mini Mitter Co, Inc. 510(k) Premarket Notification for VitalSense. Apr. 22, 2004.
Minimitter Co. Inc. VitalSense Integrated Physiological Monitoring System. Product Description. Jul. 2005.
Minimitter Co. Inc. VitalSense Wireless Vital Signs Monitoring. Temperatures.com Mar. 31, 2009.
Mojaverian et al., “Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition” Gastroenterology (1985) 89:(2): 392-7.
NPL_AntennaBasics.pdf, Radio Antennae, http://www.erikdeman.de/html/sail018h.htm; (2008) 3pp.
O'Brien et al., “The Production and Characterization of Chemically Reactive Porous Coatings of Zirconium Via Unbalanced Magnetron Sputtering” Surface and Coatings Technology (1996) 86-87; 200-206.
Owano, N., “Study proposes smart sutures with sensors for wounds” phys.org. Aug. 2012. http://phys.org/news/2012-08-smart-sutures-sensors-wounds.html.
“PALO Bluetooth Baseband” PALO Bluetooth Resource Center (2002) Retrieved from internet Dec. 12, 2012 at URL:http://palowireless.com/bluearticles/baseband.asp; first cited in Office Action dated Jan. 17, 2013 for EP08853901.0.
Park, “Medtronic to Buy MiniMed for $3.7 Billion” (2001) HomeCare; http://homecaremag.com/mag/medical_medtronic_buy_minimed/; 2 pp.
Platt, D., “Modulation and Deviation” AE6EO, Foothills Amateur Radio Society; Oct. 26, 2007; 61 pp.
“RFID “pill” monitors marchers” RFID News; Jul. 2008 http://www.rfidnews.org/2008/07/23/rfid-pill-monitors-marchers/.
Rolison et al., “Electrically conductive oxide aerogels: new materials in electrochemistry” J. Mater. Chem. (2001) 1, 963-980.
Roulstone, et al., “Studies on Polymer Latex Films: I. A study of latex film morphology” Polymer International 24 (1991) pp. 87-94.
Sanduleanu et al., “Octave tunable, highly linear, RC-ring oscillator with differential fine-coarse tuning, quadrature outputs and amplitude control for fiber optic transceivers” (2002) IEEE MTT-S International Microwave Symposium Digest 545-8.
Santini, J.T. et al, “Microchips as controlled drug delivery-devices”, Agnew. Chem. Int. Ed. (2000), vol. 39, p. 2396-2407.
“SensiVida minimally invasive clinical systems” Investor Presentation Oct. 2009 28pp; http://www.sensividamedtech.com/SensiVidaGeneralOctober09.pdf.
Shawgo, R.S. et al. “BioMEMS from drug delivery”, Current Opinion in Solid State and Material Science 6; May 2002, p. 329-334.
Shin et al., “A Simple Route to Metal Nanodots and Nanoporous Metal Films”; Nano Letters, vol. 2, No. 9 (2002) pp. 933-936.
Shrivas et al., “A New Platform for Bioelectronics-Electronic Pill”, Cummins College, (2010).; http://www.cumminscollege.org/downloads/electronics_and_telecommunication/Newsletters/Current%20Newsletters.pdf; First cited in third party client search conducted by Patent Eagle Search May 18, 2010 (2010).
“Smartlife awarded patent for knitted transducer” Innovation in Textiles News: http://www.innovationintextiles.com/articles/208.php; 2pp. Aug. 2009.
“The SmartPill Wireless Motility Capsule” Smartpill, The Measure of GI Health; May 2010 http://www.smartpillcorp.com/index.cfm?pagepath=Products/The_SmartPill_Capsule&id=17814.
Solanas et al., “RFID Technology for the Health Care Sector” Recent Patents on Electrical Engineering (2008) 1, 22-31.
Soper, S.A. et al. “Bio-Mems Technologies and Applications”, Chapter 12, “MEMS for Drug Delivery”, p. 325-346 (2007).
Swedberg, “University Team Sees Ingestible RFID Tag as a Boon to Clinical Trials” RFID Journal Apr. 27, 2010; http://www.rfidjournal.com/article/view/7560/13pp.
Tajalli et al., “Improving the power-delay performance in subthreshold source-coupled logic circuits” Integrated Circuit and System Design. Power and Timing Modeling, Optimization and Simulation, Springer Berlin Heidelberg (2008) 21-30.
Tatbul et al., “Confidence-based data management for personal area sensor networks” ACM International Conference Proceeding Series (2004) 72.
Tierney, M.J. et al “Electroreleasing Composite Membranes for Delivery of Insulin and other Biomacromolecules”, J. Electrochem. Soc., vol. 137, No. 6, Jun. 1990, p. 2005-2006.
Trutag, Technologies, Inc., Spectral Microtags for Authentication and Anti-Counterfeiting; “Product Authentication and Brand Protection Solutions”; http://www.trutags.com/; downloaded Feb. 12, 2013; 1 pp.
U.S. Appl. No. 12/238,345, filed Sep. 25, 2008, Hooman et al., Non-Final Office Action dated Jun. 13, 2011 22pp.
Walkey, “MOSFET Structure and Processing”; 97.398* Physical Electronics Lecture 20; First in Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 24 pp.
Watson, et al., “Determination of the relationship between the pH and conductivity of gastric juice” Physiol Meas. 17 (1996) pp. 21-27.
Wongmanerod et al., “Determination of pore size distribution and surface area of thin porous silicon layers by spectroscopic ellipsometry” Applied Surface Science 172 (2001) 117-125.
Xiaoming et al., “A telemedicine system for wireless home healthcare based on bluetooth and the internet” Telemedicine Journal and e-health (2004) 10(S2): S110-6.
Yang et al., “Fast-switching frequency synthesizer with a discriminator-aided phase detector” IEEE Journal of Solid-State Circuits (2000) 35(10): 1445-52.
Yao et al., “Low Power Digital Communication in Implantable Devices Using Volume Conduction of Biological Tissues” Proceedings of the 28th IEEE, EMBS Annual International Conference, Aug. 30-Sep. 3, 2006.
Zimmerman, “Personal Area Networks: Near-field intrabody communication” IBM Systems Journal (1996) 35 (3-4):609-17.
Description of ePatch Technology Platform for ECG and EMG, located it http://www.madebydelta.com/imported/images/DELTA_Web/documents/ME/ePatch_ECG_EMG.pdf, Dated Sep. 2, 2010.
Zworkin, “A Radio Pill” Nature, (1957) 898, 179 Nature Publishing Group.
Kim et al., “A Semi-Interpenetrating Network System for a Polymer Membrane”; Eur. Polym. J. vol. 33 No. 7; pp. 1009-1014 (1997).
Winter, J. et al. “The material properties of gelatin gels”; USA Ballistic Research Laboratories, Mar. 1975, p. 1-157.
Kendle, Earl R. and Morris, Larry A., “Preliminary Studies in the Development of a Gastric Battery for Fish” (1964). Nebraska Game and Parks Commission White Papers, Conference Presentations, & Manuscripts. Paper 22. p. 1-6.
Whipple, Fred L.; “Endoradiosonde,” Nature, Jun. 1957, 1239-1240.
Au-Yeung, K., et al., “A Networked System for Self-Management of Drug Therapy and Wellness”, Wireless Health '10, Oct. 5-7, 2010, San Diego, 9 pages.
Consolvo, Sunny et al., “Design Requirement for Technologies that Encourage Physical Activity,” CHI 2006 Proceedings, Designing for Tangible Interactions, Apr. 22, 2006, Montreal, Quebec, Canada, pp. 457-466.
Ferguson et al., “Wireless communication with implanted medical devices using the conductive properties of the body,” Expert Rev Med Devices, Jul. 2011, 8(4): 427-433.
Greene, “Medicaid Efforts to Incentivize Healthy Behaviours”, Center for Health Care Strategies, Inc., Resource Paper, Jul. 2007.
McDermott-Wells, P., “What is Bluetooth?”, IEEE Potentials, IEEE, New York, NY, vol. 23, No. 5, Dec. 1, 2004, pp. 33-35.
Chan, Adrian D.C., et al.,; “Wavelet Distance Measure for Person Identification Using Electrocardiograms,” IEEE Transactions on Instrumentation and Measurement, IEEE Service Center, Piscataway, NJ, US, vol. 57, No. 2, Feb. 1, 2008, pp. 248-253.
Zhang, Y-T. et al., “Wireless Biomedical Sensing,” Wiley Encyclopedia of Biomedical Engineering, 2006, pp. 1-9.
Aronson, J., “Meyer's Side Effects of Cardiovascular Drugs,” Elsevier, Mar. 2, 2009, Medical , 840 pages. (Not Attached).
Herbig, S.M., “Asymmetric-membrane tablet coatings for osmotic drug delivery”, Journal of Controlled Release 35 (1995) 127-136.
Lee, K. B.; “Two-step activation of paper batteries for high power generation: design and fabrication of biofluid- and wateractivated paper batteries”; J. Micromech. Microeng. 16 (2006) 2312-2317.
Lee, K. B.; “Urine-activated paper batteries for Biosystems”; J. Micromech. Microeng. 15 (2005) S21 O-S214.
Sammoura, F. et al., “Water-activated disposable and long shelf life microbatteries”, Sensors and Actuators A 111 (2004) 79-86.
VonStetten, F. et al., “Biofuel cells as power generation for implantable devices”, Pore. Eurosensors XX, (2006), pp. 22-225.
Van der Biest, O., et al., “Electrophoretic deposition of materials,” Annu. Rev. Mater. Sci. 1999, 29: pp. 327-352.
Browne, S.H., et al., “Let visuals tell the story: Medication adherence in patients with type II diabetes captured by a novel ingestion sensor platform,” JMIR Mhealth Uhealth; 3(4): e108; 2015; 27 pages.
Frias, J. et al., “Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial,” J Med Internet Res, 2017;19(7):e246; p. 15 (16 pages).
Noble et al., “Medication adherence and activity patterns underlying uncontrolled hypertension: Assessment and recommendations by practicing pharmacists using digital health care,” JAPHA; 56 (2016) pp. 310-315 (6 pages).
Savage, G., “Predictive Analytics: Advancing Precision and Population Medicine,” Harvard Health Policy Review, 2015; vol. 14; Issue 2; 4 pages.
Related Publications (1)
Number Date Country
20130073312 A1 Mar 2013 US
Provisional Applications (1)
Number Date Country
61346035 May 2010 US